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Breast cancer (BC) is the most common malignancy in women with the second highest 
cancer related mortality rate [1]. BC is a heterogeneous disease and comprises different 
subtypes defined by immunohistochemistry: estrogen receptor (ER) and/or progesterone 
receptor (PR) positive BC, BC with human epidermal growth factor receptor 2 (HER2) 
amplification and triple negative breast cancer (TNBC), which is characterized by the 
absence of expression of ER/PR/HER2. Another method for categorizing BC is by their 
distinct molecular patterns, which classifies BC into five intrinsic subtypes with variable 
clinical outcomes: luminal A, luminal B, HER2 over-expression, basal and normal-like 
tumors [2, 3].
 Most BCs occur sporadically, but in approximately 15-20% of the cases there is a 
positive family history for the disease [4]. These so-called familial BCs often have germline 
mutations in one of several BC susceptibility genes (BRCA1, BRCA2, CHEK2, PALB2, PTEN, 
TP53 and ATM)[5]. However, in more than half of the familial BC cases these genes remained 
unaffected, thus the underlying genetic variation causing the increased BC risk remains 
unknown. Approximately 3% of all BC cases are due to germline mutations in BRCA1/2 [6], 
and in TNBC this percentage is even 10-20% [7].  
Prediction of therapy response
Various systemic therapies, ranging from classic chemotherapy to personalized targeted 
treatments, are available for BC treatment. Proper selection of patients who are most likely 
to benefit from these treatment regimens is of utmost importance. Biomarker-driven 
research has yielded strong predictive biomarkers that correlate with patient response 
to a certain drug. For example, the monoclonal antibody trastuzumab, targeting HER2, 
dramatically improved survival for patients with BC overexpressing HER2 [8]. However, 
predictive biomarkers for classic chemotherapies do not yet exist. 
 Besides specific molecular markers (e.g. EGFR mutation status in non-small cell lung 
cancer [9], BRCA mutation status in BC [10]), the field of biomarker discovery has moved to 
genomic, transcriptional and proteomic predictive signatures [11-13]. More recently, whole-
genome sequencing was exploited to characterize individual patients and predict therapy 
response [5, 14-17]. However, validation of these biomarkers and subsequent integration in 
the diagnostic process are major bottle-necks that require extensive research. For example, 
there are concerns regarding turn-around time of the generation of these biomarkers, 
what to do with variants of unknown significance, whether the tests detect historic events 
or reflect real-time tumor characteristics and how to cope with complex data analyses. 
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BRCA and Homologous Recombination
Germline BRCA1/2 mutation status is the predictive biomarker for PARP inhibitor treatment 
[18-20]. The BRCA1/2 genes are essential for the repair of DNA double strand breaks (DSB) 
through the homologous recombination (HR) pathway. If the DSBs are left unrepaired, 
this will lead to genomic instability and eventually cell death [21]. The HR pathway ensures 
error-free repair of DSBs during S- and G2-phase of the cell cycle [22] (Figure 1). RAD51 is 
one of the proteins involved in this pathway and forms a nucleoprotein filament around 
the single-stranded DNA flanking the DSB, promoting the strand exchange with the sister 
chromatid for the repair (Figure 1). In HR deficient (HRD) tumors the HR pathway is not 
capable of repairing the DSBs. Besides germline BRCA1/2 mutations, HRD can also be 
caused by somatic BRCA1/2 mutations and BRCA1 promoter hypermethylation, as well 
as via other mechanisms than loss of BRCA (e.g. PALB2 inactivation [23]). It has been shown 
that BRCA deficient tumors respond well to PARP inhibitor treatment [18, 19], which works 
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Figure 1: The homologous recombination (HR) pathway ensures error-free repair of DSBs. HR occurs 
during S and G2 phase of the cell cycle, as the sister chromatid is then present to serve as a template to faithfully 
restore the DNA. When a DSB has arisen, due to irradiation or DSB causing chemotherapy, the first step towards 
DNA repair via the HR pathway is end-resection, resulting in single-stranded DNA through 5’-3’ exonucleolytic 
activity. During this step, multiple proteins are involved, including BRCA1. This single-stranded DNA is coated by 
RPA, which is subsequently replaced by RAD51. RAD51 loading on the DNA is mediated by BRCA2 and PALB2. 
RAD51 forms a nucleoprotein filament around the single-stranded DNA, which allows strand invasion of the 
sister chromatid and D-loop formation. Lastly, the invading 3’ strand is elongated by DNA polymerases and the 
DSB is resolved. The HR pathway is comprised of multiple sub-pathways [34], and for simplicity only one (the DSBR 



















Figure 2: Mechanism of PARP inhibition. Single strand DNA breaks (SSBs) occur frequently and require 
Poly(ADP-ribose) polymerase I (PARP-I) for efficient repair. Upon treatment with a PARP-inhibitor, the SSBs repair 
is attenuated and as a consequence unrepaired SSBs convert into double strand DNA breaks (DSBs) upon DNA 
replication. These DSBs require the HR pathway for their repair. However, if the HR pathway is not properly 
functioning (i.e. HR deficiency), the DSBs cannot accurately be repaired and will accumulate, leading to cell 
death.
Synthetic lethality and PARP inhibition
Synthetic lethality occurs when there is a combination of two deficiencies, while only one 
of these deficiencies is still compatible with life. More specifically, in case of PARP inhibition, 
the combination of HRD and inhibition of the PARP enzyme leads to specific tumor cell 
killing (Figure 2). The PARP enzyme is involved in DNA repair of DNA single strand breaks 
(SSB). Through PARP inhibition, SSBs are not repaired as efficiently anymore and upon 
DNA replication these SSBs are converted to DSBs, which require the HR pathway for their 
repair [24, 25]. In addition, PARP inhibition leads to trapping of PARP molecules on the DNA, 
thereby preventing DNA replication and transcription, leading to cell death. In tumor cells 
of BRCA1/2 gene mutation carriers both BRCA alleles are affected, leading to HRD, which 
in combination with PARP inhibition leads to specific cell death. In healthy cells of BRCA1/2 
gene mutation carriers only one of the two alleles is affected, leaving the HR pathway 
intact and consequently the healthy cells remain unharmed as synthetic lethality does 
not occur (Figure 2). Thus, PARP inhibitors offer an elegant and targeted treatment for 
HRD tumors. 
Germline BRCA1/2 mutation status is currently the only predictive biomarker for PARP 
inhibitor treatment. However, the population of BC patients who could benefit from PARP 
inhibitor treatment can be enlarged through patient selection based on the HRD status 
of the tumor, instead of germline BRCA mutation status. Various HRD tests have been 
developed to identify HRD tumors in addition to germline BRCA mutated tumors [15, 26-28]. 
Chapter 1
4
In this thesis, the REpair CAPacity (RECAP) test is presented, a functional assay exploiting 
the formation of RAD51 foci in proliferating cells after ex vivo irradiation of fresh BC tissue 
[27, 29, 30].  
Tissue-based functional analyses
As therapy response often cannot be predicted accurately by a single genetic marker only, 
alternative ways of patient stratification are needed. Beyond mutational status, many other 
factors influence tumor behavior and therapy response, for example epigenetic factors 
and the tumor microenvironment [31, 32]. For instance, although HER2 amplification is a 
strong predictive marker of response to trastuzumab in BC patients, its predictive value 
in gastric cancer is much weaker [33]. Therefore, the current difficulty to translate genetic 
information to tumor behavior necessitates development of tools to select patients for 
therapies based on tumor phenotype rather than genotype. Ex vivo assays that predict 
therapy response may fill this knowledge gap.
 Prediction of individual treatment responses by functional ex vivo assays require a 
viable sample from the tumor, which is then cultivated in the laboratory and exploited 
for drug screening or other ex vivo functional testing. The model systems derived from 
viable tumor samples should closely resemble the in vivo tumor characteristics and 
microenvironment. A broad spectrum of model systems, ranging from classic 2D monolayer 
culture techniques to more experimental ‘cancer-on-chip’ procedures, are discussed in 
chapter 2. Organotypic tissue slices are the model system used for the functional ex vivo 
assays described in this thesis. 
The aims and scope of this thesis
The general aim of this thesis is to improve biomarker development and therapy response 
prediction for BC patients using functional tissue-based assays.
Chapter 1 introduces BC and more specifically elaborates on BRCA gene defects and 
prediction of therapy response. 
Chapter 2 provides an overview of ex vivo tumor culture systems for functional drug 
testing and therapy response prediction. This review article highlights the advantages 
and disadvantages of several ex vivo tumor culture systems such as primary cultures, 
spheroids, organoids and tissue slices.
The aim of the study described in chapter 3 is to validate the REpair CAPacity (RECAP) test, 
a functional assay exploiting the formation of RAD51 foci in proliferating cells after ex vivo 
irradiation of fresh BC tissue, in an extensive cohort of primary BCs and provide evidence 




molecular characterization of the HRD phenotype is performed, proving that HRD tumors 
encompass more than only BRCA deficiencies.
In chapter 4 we aim to show feasibility of the RECAP test on biopsies from metastatic BC 
lesions to enhance the diagnostic potential and clinical applicability of this test. Next, we 
aim to find a molecular explanation for the observed HRD phenotype and we explore the 
utility of the RECAP test as a predictive tool for treatment with DSB inducing agents and 
PARP inhibitors in this setting. This chapter demonstrates that functional HR assessment 
by the RECAP test produces a unique real-time measure of the HR status.
In chapter 5, we investigate whether the HRD tumors, especially the non-BRCA related 
HRD tumors, identified by the RECAP test would also be detected by other HRD tests. 
To this end, a large cohort (n=71) of breast tumors with known functional HR status, 
measured by RECAP, is subjected to other genomic scar based HRD tests (BRCA1/2-like 
classifier and CHORD). For a subset (n=54) whole genome sequencing is performed to 
further characterize HRD tumors and especially the non-BRCA related HRD tumors. For a 
small subset HRD status is linked to clinical outcome data.
Chapter 6 describes the development of an ex vivo sensitivity assay for DSB inducing 
anticancer drugs (in particular cisplatin) on histological biopsies. First, we establish the 
optimal conditions for the ex vivo sensitivity assay in organotypic tissue slices from patient 
derived xenograft (PDX) tumors with known in vivo cisplatin sensitivity. The next step is 
to perform ex vivo treatment on organotypic tissue slices from primary breast tumors as 
well as from histological biopsies of metastatic BC lesions. We compare the results of the 
ex vivo sensitivity assay to several parameters associated with cisplatin response, such as 
BRCA mutation, TNBC and HR status. Finally, the ex vivo responses are correlated with the 
in vivo responses among those patients who were subsequently treated with a platinum 
containing chemotherapeutic regimen.
In chapter 7, we perform a comprehensive characterization of our large collection of 
breast and ovarian cancer cell lines to identify the functional HR status and to study the 
discrepancies between functional HR and BRCA mutation status. We hypothesized that 
the functional HRD status of cell lines would better reflect the real-time HR status of the 
cell line at the time of testing than BRCA mutation status. The functional HRD status is 
correlated to gene expression and methylation data for a panel of known HRD genes, as 
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Ex vivo tumor culture systems for 
functional drug testing and therapy 
response prediction 
Abstract
Optimal patient stratification is of utmost importance in the era of personalized medicine. 
Prediction of individual treatment responses by functional ex vivo assays require model systems 
derived from viable tumor samples, which should closely resemble in vivo tumor characteristics 
and microenvironment. This review discusses a broad spectrum of model systems, ranging from 
classic 2D monolayer culture techniques to more experimental ‘cancer-on-chip’ procedures. 
We mainly focus on organotypic tumor slices that take tumor heterogeneity and tumor-stromal 
interactions into account. These 3D model systems can be exploited for patient selection as well as 
for fundamental research. Selection of the right model system for each specific research endeavor is 
crucial and requires careful balancing of the pros and cons of each technology.
Lay Abstract
Selection of the right therapy for individual cancer patients is very important with the expanding 
number of possible treatments. How tumors respond to a therapy can be tested by treating a 
sample from the tumor outside the body. Various culture methods can be used to maintain this 
tumor sample. Each of these model systems has its own benefits and disadvantages. In this review, 
we discuss the advantages and drawbacks of the available model systems and how they can be 
used to guide personalized medicine.




Treatment of epithelial cancers generally comprises surgical resection, radiation and/or 
systemic therapy. Systemic therapies traditionally consist of chemotherapeutic agents. 
Recently, more and more targeted therapies, such as small molecule inhibitors and 
monoclonal antibodies, have been developed. Targeted therapies have the potential 
advantage that they are directed against specific characteristics unique to the tumor cells, 
leaving the surrounding healthy tissue relatively unharmed. Over the last decades, cancer 
treatment has moved from ‘one-size-fits-all’ regimens towards more personalized cancer 
therapy. Molecular characteristics of the tumor cells are now used for therapy selection. 
For example, the monoclonal antibody trastuzumab, targeting the Human Epidermal 
growth factor Receptor 2 (HER2), dramatically improved survival for patients with breast 
tumors overexpressing HER2 [1]. These positive developments pose new challenges: 
proper selection of patients that are most likely to benefit from these targeted treatment 
regimens.
 Adequate patient selection requires extensive molecular characterization of individual 
tumors. The search for predictive biomarkers started with specific molecular markers 
(e.g. EGFR mutation status in non-small cell lung cancer [2]) and developed over time into 
genomic, transcriptional and proteomic signatures [3-5]. In the future, next-generation 
sequencing techniques will be exploited to characterize individual patients molecularly 
and predict therapy response. However, validation of these biomarkers and subsequent 
implementation in the clinic are major bottle-necks that require extensive research. 
 As therapy response often cannot be predicted accurately by a single genetic marker 
only, alternative ways of patient stratification are needed. Beyond mutational status, many 
other factors influence tumor behavior and therapy response, for example epigenetic 
factors and the tumor microenvironment [6,7]. For instance, although HER2 amplification 
is a strong predictive marker of response to trastuzumab in breast cancer patients, its 
predictive value in gastric cancer is much weaker [8]. Therefore, the current difficulty to 
translate genetic information to tumor behavior necessitates development of tools to 
select patients for therapies based on tumor phenotype rather than genotype. Ex vivo 
assays that predict therapy response may fill this knowledge gap. 
 These functional assays require a viable sample from the tumor, which is then 
cultivated in the laboratory and exploited for drug screening or other ex vivo functional 
testing. Obviously, these tests require optimal model systems, which most closely 
resemble the in vivo tumor characteristics and microenvironment. Established tumor cell 
lines and genetically engineered mouse models are time consuming and do not represent 
the variation and heterogeneity observed in cancers from patients. Therefore, these 
models are usually not the optimal choice for development of assays to select patients 
for personalized cancer treatments [9]. Many alternative model systems are emerging 
to overcome these drawbacks and resemble in vivo tumors more closely. These model 
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systems enable execution of various ex vivo functional tests that aim to predict therapy 
response in the patient. We here discuss generation of two-dimensional (2D) and three-
dimensional (3D) tumor cell culture methods, patient-derived xenografts (PDX) and 
organotypic tumor tissue slices (Figure 1). We here review the benefits and disadvantages 
of the available (preclinical) cancer model systems. 
2D monolayer culture of dissociated tumor cells
To obtain a 2D monolayer of cells, the tumor is dissociated by specific proteolytic enzymes 
such as collagenase, dispase and/or trypsin. Depending on the tumor type, enzymatic 
digestion is combined with mechanical dissociation for better dispersal of the tumor mass [10]. 
Not all tumors can be cultured ex vivo in monolayers. The need to adhere to the culture 
dish obviously causes a selection bias for adherent cells. Two types of 2D monolayer 
cultures exist: primary (tumor) cell cultures and cancer cell lines. Primary cell cultures are 
heterogeneous and represent the original tumor more closely but do not possess the 
limitless proliferative capacity that cancer cell lines have. Cancer cell lines are defined as 
clonal outgrowths from a primary tumor cell culture. 
 Once dissociated tumor cells successfully form a 2D monolayer in vitro, characterization 
of these cells can be performed in various ways. Primary (tumor) cell cultures can be 
exploited for diagnostic testing. Compared to cancer cell lines, primary cell cultures have 
less clonal selection and allow several short term functional analyses. This works well for 
some tumor types, such as bladder tumor cell cultures that have been used to  characterize 
Nucleotide Excision Repair (NER) activity [10]. 
 Primary (tumor) cell cultures can also be established from tumor cells found in body 
fluids, including ascites and pulmonary effusion. For example, withdrawal of excessive 
ascites from ovarian cancer patients is often performed regularly for symptom relief and 
therefore less invasive than tumor biopsies. Generation of 2D monolayer cultures from 
these tumor cells has a 90% success rate, thereby providing a model system for functional 
testing and guiding personalized medicine for these patients [11,12]. 
 Human cancer cell lines have proven invaluable in both fundamental and translational 
research. Easy handling, homogeneous character and limitless growth make this the 
model system of choice for many large high-throughput experiments. High-throughput 
drug screenings using large panels of cancer cell lines have led to the discovery of new 
drug targets and gene signatures predicting therapy responses [13,14]. 
 Successful establishment of cancer cell lines from solid tumors is often inefficient, 
because of failure to adhere to the culture dish or loss of proliferative capacity after a few 
passages (e.g. for breast cancer the success rate is between 1 and 10% [15]). Especially, slow 
growing tumors are severely underrepresented, as they do not often give rise to tumor 
cell lines. The optimal result is a clonal outgrowth and therefore cell lines do not represent 
the heterogeneity of the primary tumor. Indeed, cell lines and the in vivo tumors from 
which they originate, show many genetic, epigenetic and gene expression differences [16]. 
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 Another limitation of cell lines is the extended time required for clonal outgrowth, 
minimizing the applicability of this model as a patient selection tool for personalized 
medicine. Genetic drift and cross-contamination are other issues often encountered when 
working with cell lines. This is not a problem when using primary (tumor) cell cultures in low 
passages for diagnostic testing, but is a major concern for extended culturing of cell lines 
in a laboratory setting. The latter problem can be minimized by freezing representative 
low passage stocks [17]. 
 In conclusion, 2D culture systems do not capture the subtleties of the original tumor 
microenvironment. However, primary tumor cell cultures may represent a valid approach 
to guide personalized medicine decision making. Cancer cell lines are valuable tools for 
high-throughput drug screening, although translation of these screens to the clinic can 
be difficult. 
3D tumor cell models
The limited cell-cell interactions in 2D monolayer cultures introduce major changes in 
cellular physiology. Therefore, 3D cultures of the same cells may represent the original 
organ or tumor more faithfully than traditional cell cultures. 3D cancer cell line-based 
models have been reviewed elsewhere [18]. Although they capture some features of tumor 
cell biology better than 2D culture systems, they fail to mimic tumor heterogeneity. For 
this reason, it would be preferred to start 3D cultures from primary tumor cells and/or 
tumor stem cells instead of cancer cell lines.
 Some decades ago, collagen gels floating in the culture medium were shown to allow 
epithelial cells from different origins to form alveolus-like structures and maintain tissue 
function and differentiation [19]. This was the beginning of ex vivo culturing of normal 
epithelial cells, such as mammary acini and colonic crypts, as functional units. 
 More recently, these 3D culture systems have been adapted such that they can 
grow for many passages. Such organoids can be established through isolation of adult 
stem cells and subsequent embedding of the cells in a three-dimensional matrix. The 
undifferentiated stem cells (e.g. Lgr5+ cells) are stimulated by supplements of tissue 
specific exogenous growth factors, in addition to growth factors endogenously produced 
by the stem cell microenvironment and surrounding mesenchyme [20]. They self-organize 
into epithelia of the respective organ of origin, such as intestinal stem cells giving rise to 
formation of mini-guts, representing the epithelial architecture of the small intestine and 
colon [21]. 
 Similar technology allows 3D culture of tumor cells in spheroid structures; often 
referred to as tumor organoids. This technique can achieve long-term ex vivo expansion of 
tumor cells that still represent the heterogeneity of the original tumor [22]. Tumor organoid 
growth can have a high success rate, even when starting material is limited [23]. Up to date, 
successful human tumor derived organoids have been created from many different tumor 
types, including colorectal, stomach, liver and pancreas cancers [22,24-26]. Recently, tumor 
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organoids have also been grown from frozen material, greatly extending the applicability 
of this technique [27]. However, it remains to be demonstrated whether tumor organoids 
can be grown with similar efficiencies from other tumor types. 
 The introduction of organoid cultures has created novel opportunities for high-
throughput drug screens aiding personalized cancer treatment, biomarker discovery and 
studies on drug resistance mechanisms. A living organoid biobank for colorectal cancer 
patients is currently being collected, allowing gene expression analysis to detect gene-
drug associations. Ideally, drug screens on these tumor organoids point towards effective 
personalized treatment strategies [28]. 
 However, some drawbacks of the technique have surfaced, as well. The requirement 
of a collagen gel for 3D culturing was the initial break-through, yet seems to complicate 
potential drug screening and makes culturing more labor intensive. 
 Moreover, tumor organoids derived from a homogenous population of stem cells do 
not harbor the microenvironment of in vivo tumors, which also include non-transformed 
cells such as stromal fibroblasts and infiltrating immune cells. However, this technique 
can be developed further by introducing additional heterogeneity through patient-
matched co-cultures with organoids grown from normal tissue adjacent to the tumor. 
Hybrid organoids consisting of tumor cells and stromal cells show promising potential for 
unraveling metastatic processes and tumor-stroma characteristics [29]. These co-cultures can 
also be adapted for other 3D culturing techniques to mimic the tumor microenvironment. 
For example, the development of 3D tumor co-cultures from cancer cell lines grown in 
combination with fibroblasts, endothelial cells, immune cells or bone cells enable crosstalk 
between tumor cells and the stromal cells of the microenvironment [30-33]. 
 Organoid culture systems are suboptimal as a diagnostic tool, since their generation 
takes several weeks and clinical diagnostic testing for individual therapy selection should 
be conclusive within a much shorter timeframe [28]. On the other hand, one could envision 
organoid generation from primary tumor or metastasis material of patients treated with 
chemotherapy. Simultaneous treatment of the tumor organoid with various therapeutics 
could guide further therapy selection for these patients. The correlation between organoid 
and in vivo tumor therapy response would require extensive validation in this case. 
 In conclusion, 3D organoid cultures are valuable tools for drug screens, biomarker 
discovery and studies on drug resistance mechanisms. Nevertheless, this model lacks 
the complexity of the tumor microenvironment and is less suited to guide personalized 
medicine.
Patient-derived Xenografts (PDX)
Dissociation of the tumor tissue is a prerequisite for 2D monolayer cultures and tumor 
organoids. This leads to loss of tumor heterogeneity and outgrowth of a specific 
subset of tumor cells. Another method to expand and preserve individual tumors from 
cancer patients is implantation of fresh pieces of the tumor in immune-deficient mice, 
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subcutaneously or in a place that more closely resembles the original tumor location [34,35]. 
These so-called patient-derived xenograft (PDX) tumor models retain intra-tumor 
heterogeneity [36]. The first PDX models were generated in the 1980s and they are still 
important and widely used in cancer research [37]. PDX models have been exploited for 
drug screening, biomarker discovery, identification of resistance mechanisms and pre-
clinical evaluation of (personalized) treatment strategies [34]. PDX models maintain several 
characteristics of the in vivo tumor, including histopathological features, gene expression 
profiles, copy number variation and metastatic behavior [38-41]. 
 Systematic analysis of PDX models enables biobanking of genomically well-defined 
tumors [34]. These biobanks are valuable resources for developing new predictive or 
prognostic biomarkers and individualized treatment strategies, thereby potentially 
guiding personalized medicine [42]. Also, co-clinical trials have been designed, in which 
PDX models are treated with anti-cancer therapies in parallel with the same treatment of 
patients in clinical trials [43,44].  The co-clinical trial concept allows integration of preclinical 
and clinical data, facilitating personalized treatment selection for patients, discovery of 
predictive biomarkers and identification of resistance mechanisms. Whether responses to 
chemotherapy observed in PDX models resemble the response rates of patients in clinical 
trials still remains to be elucidated [45,46]. 
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Increasing Tumor Complexity and heterogeneity 
Figure 1: Comparison of ex vivo tumor culture techniques. Fresh viable tumor tissue can be preserved and 
cultured ex vivo in several ways, each having its own advantages and disadvantages. A tumor sample can be 
dissociated using enzymatic and/or mechanical methods and subsequently cultured either as a 2D monolayer or 
in a 3D tumor spheroid culture. To mimic the in vivo situation as much as possible dissected tumor samples can 
be implanted in immunodeficient mice to generate patient-derived xenograft models. Organotypic tumor tissue 
slices can be generated by precision slicing of a tumor specimen, keeping general tumor/tissue architecture 
intact.
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More recently, a pilot study with a similar concept was carried out. Treatments for patients 
with advanced cancer were selected on the basis of activity against a personalized 
tumorgraft derived from the in vivo tumor [47]. These personalized tumor graft models led 
to selection of a treatment regimen for 12 out of 14 patients. The treatments selected for 
each individual patient were not obvious and would not have been the first choice for a 
conventional second or third line treatment. In 9 out of 12 patients the selected treatment 
resulted in durable partial remission [47]. These results are quite striking, since the expected 
response rate with phase I agents, the only available option for some of these patients, is 
less than 10% [48]. These results need to be confirmed in larger cohorts of patients to get 
a better idea of the level of concordance between response in personalized tumorgraft 
models and the tumor of origin. 
 While ingenious advancements have been made in PDX applications, PDX models 
still harbor some important disadvantages. The first major drawback is the variable 
success rate of tumor engraftment [47]. Therefore, the variation observed in the cancer 
patient population may not be recapitulated faithfully in PDX models due to this selective 
engraftment rate [34]. Clinically aggressive tumors with many proliferative cancer cells, 
have the highest engraftment rate [49,50]. 
 A second major drawback is the long generation time of PDX models, which limits 
their use in personalized medicine. The time between implantation and progressive 
growth of the xenograft tumor (PDX generation time or tumor graft latency) can range 
from 2 to 12 months [51,52]. In case of metastasized disease, patients may not even survive 
the PDX generation time [51]. PDX models may have limited use in diagnostics due to their 
low-throughput character and relatively high costs. 
 In addition to these practical problems for use of PDX models in personalized medicine, 
their use is also somewhat limited because of fundamental imperfections of the model. 
Although they retain intra-tumor heterogeneity, they fail to maintain the heterogeneity in 
the human tumor microenvironment, as the tumor stroma is slowly substituted by mouse 
stroma upon passaging. Therefore, the contribution of tumor-stroma interaction cannot 
be deduced faithfully from PDX models for drug screening. 
 Furthermore, PDX formation requires tumor implantation in severely 
immunocompromised host animals, complicating the evaluation of tumor immunology 
and drugs targeting the immune system [53]. This problem could be circumvented by using 
mice carrying a humanized immune system, although problems with graft-versus-host 
disease limit this approach severely [54]. Thus, when studying immunotherapies or tumor-
stromal interactions there is a need for alternative model systems that allow exploration 
of the tumor microenvironment.
 Overall, PDX models harbor more intra-tumor complexity than 2D monolayers 
or various 3D culturing techniques because the tumor is not dissociated. Since the 
generation time of PDX models is rather long, this model is less suitable for drug screening 
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and personalized medicine but still important for drug validation, investigation of therapy 
resistance mechanisms and  biomarker development.
Organotypic tumor tissue slices
Various 3D culture systems have been designed to resemble in vivo tumors as closely as 
possible, taking tumor heterogeneity and tumor-stromal interactions into account. Most 
of these 3D culture approaches mimic tumor complexity only partially. The initial step for 
all techniques is dissociation of tumor tissue before the cells are stimulated to grow in 
3D. Organotypic tumor slices, on the other hand, retain the complexity of tumors in vivo 
without extensive manipulation of the tissue. This leads to a model system in which the 
tumor cells are surrounded by their original microenvironment, rather than artificial 
matrices. 
 The first publications on organotypic tissue slices originate from the 1960s involving 
cardiac and brain tissue [55]. This technique involves precision slicing of tissue using 
specifically designed machines; the Krumdieck tissue slicer was considered the golden 
standard, until more recently the vibrating blade microtome (vibratome) was introduced [56]. 
The Krumdieck tissue slicer punches a cilindrical core from the tissue, which is then sliced 
by a rotating knife. The vibratome uses a vibrating knife to cut the tissue and has lower 
mechanical impact. Tissue slicing does not interfere with morphology and functional 
activity of the tissue and was soon exploited to study many different tissues including 
liver, retina, prostate, breast and testicular tissue [57-61]. Direct comparison of the Leica 
VT1200S vibrating blade microtome and the Krumdieck tissue slicing techniques revealed 
that the vibratome produces more precise and reproducible slices [60]. However, this may 
not be true for all tumor types. For example, the Krumdieck tissue slicer outperforms the 
vibratome when slicing the viscous texture of glioblastomas [62].  


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Ex vivo drug screens and other functional tests require optimal culture conditions for 
these organotypic tumor tissue slices. Tumor slicing is usually achieved within hours of 
surgical resection of the primary tumor to minimize deterioration of the tissue and loss 
of cellular viability [63]. Short term culture of tumor tissue slices can be achieved without 
extensive optimization of culture conditions. In some cases, short term culture of tissue 
slices suffices for selection of optimal treatment strategies. For example, a functional assay 
for homologous recombination capacity has been established. This test exploits RAD51 
accumulation at DNA double strand breaks after ex vivo irradiation of tumor slices or 
biopsies to select breast cancer patients for targeted treatment with PARP inhibitors [63].  
 However, preservation of tumor slices for extended periods without losing tumor 
viability, necessary for ex vivo drug screening, required extensive optimization of media 
composition and/or culture conditions.
 Culture conditions can generally be divided in slices cultured on the bottom of the 
dish, freely floating in the medium or grown on membrane supports. This can be combined 
with rotational movement of the cultures to achieve optimal diffusion of oxygen and 
nutrients. Some studies report growth under low oxygen conditions [64], but this in general 
leads to low tumor slice viability. Culture media that have been used are very diverse. The 
basis is generally one of the commercially available media for cell culture, supplemented 
with fetal bovine serum and antibiotics. Furthermore, various growth factors have been 
added to optimize conditions for specific tumor types. 
 Tissue slices can be cultured on Teflon membrane inserts, which have 0.4-μm pores 
that allow preservation of 3D tissue structure in culture and position the tissue slice at the 
air/liquid interface enabling efficient oxygenation. Colon, lung, head and neck, gastric, 
esophageal and prostate cancer slices have been reported to be preserved by incubation 
on Teflon membrane inserts [65-67]. Davies et al have extensively studied the impact of 
various incubation methods [64]. They found that tumor transportation and slicing had little 
impact on stress protein expression, whereas different cultivation methods significantly 
changed tissue vitality and expression of stress proteins. Vitality of tumor slices of various 
origins was maintained better when cultured on a membrane support compared to 
on the bottom of a culture dish. Although, even under these conditions, changes were 
observed in the slices after a few days in culture. Cultivation of the slice on the bottom of 
a culture dish led to significant alteration of a number of stress pathways and loss of tissue 
integrity, which can probably be explained by lack of oxygen and nutrient exchange. 
To overcome this issue, tissue slices can be incubated while floating in medium, which 
can be achieved via continuous movement using an orbital shaker. Breast cancer slice 
viability was preserved for prolonged periods of time when slices were incubated under 
constant rotation. Slices from the same breast tumor cultured under rotation showed 
more proliferating cells after 48 hours compared to slices cultured in static conditions [68]. 
Breast cancer slices, obtained via vibratome slicing and cultured under constant rotation, 
remained vital for 7 days [68] (Table 1). 
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 Prolonged culture of tumor slices is an absolute requirement for investigation of 
cytotoxic drug responses. Improved efficiency of drug response prediction is clearly 
needed, since only 7.5% of the anti-cancer compounds tested in Phase I clinical trials 
eventually obtains approval [69]. One of the main reasons for this disappointing percentage 
is the use of preclinical models that do not represent the complexity of in vivo tumors [70]. 
Organotypic tissue slices could serve as a model to examine response of the tumor to 
anti-cancer compounds ex vivo, as it most closely resembles the heterogeneity and 
microenvironment of in vivo tumors. Indeed, cytotoxic responses to targeted therapies as 
well as classic chemotherapeutic agents have been predicted in organotypic tissue slices 
[61,65-68,71]. Also in this case, concordance between ex vivo sensitivity and in vivo treatment 
response rates still remains to be validated. For this purpose, pre-treatment biopsies 
should be obtained for ex vivo sensitivity assays, subsequently comparing these results 
to in vivo post-treatment response evaluations. Therefore, the tissue slicing technique 
and incubation should be optimized for biopsy specimens, taking the first steps towards 
clinical validation and subsequent diagnostic application of this model system. 
 A major disadvantage of tumor tissue slices as a method for drug testing is its relatively 
low-throughput. The technique is rather laborious and requires specialized analysis tools 
that may not be easily implemented outside research settings. Markers that are generally 
used for determining response are analyzed by immunofluorescent microscopy and 
quantification of these markers is still challenging. Therefore, it is to be expected that this 
culture system will only be used in a laboratory setting and connected to clinical studies 
in the near future. Depending on the concordance between ex vivo outcomes and tumor 
response in patients, these methods could be adapted for a more routine clinical setting. 
However, automation of the processing and read-out is not easily possible and will require 
technical adaptations such as a cancer-on-chip approach described below. 
 Hypoxia is another potential problem of organotypic tissue slice cultures as a model 
system [72]. Because intact vascularity is absent in tissue slices, the amount of oxygen 
available is limited to gas diffusion. Several parameters influence this oxygen diffusion, 
such as slice thickness, matrix stiffness, cellularity and metabolic and proliferative 
activity of the tumor and stromal cells [68,72]. Especially long term cultures with extensive 
proliferation of tumor cells may cause hypoxia in the center of these growing tumor slices. 
On the other hand, organotypic tissue slices may allow detailed investigation of gradients 
of oxygen tension observed in patient tumors in a controlled setting in vitro [72].
 A drawback of many model systems, including organotypic tissue slices, is the lack 
of systemic features such as an immune system. The engineering of personalized tumor 
ecosystems, which conserve the microenvironment through cultivation of tissue slices in 
defined tumor grade-matched matrix support and in the presence of autologous serum, 
may be a next step in organotypic tissue slice cultivation [73]. In these personalized tumor 
ecosystems, patient serum derived immune cells could infiltrate the tissue slice, extending 
the possible applications of this model system.  
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 To conclude, organotypic tissue slices represent a solid model system for functional 
assays and drug sensitivity testing for personalized medicine, due to its fast generation 
time and reflection of intra-tumor heterogeneity and tumor-stromal interactions. 
However, many different methods for cultivation of organotypic tissue slices exist and the 
optimal system remains to be selected. 
 Although many publications on tumor slice cultures lack careful comparison of 
culture conditions and are not easily comparable to each other, a common denominator 
begins to emerge from the literature. Tissue slices from various tumor types, including 
lung, prostate, colon, gastric and head and neck cancer have been cultured for several 
days [65-68]. Glioblastoma tissue slices remained vital and still harbored histological 
characteristics of the original tumor even after 16 days of culture [62]. Different tumors 
require different culture conditions. Highly proliferative tumors, for instance, require 
more oxygen exchange, whereas very fragile tissue slices benefit from incubation on 
supportive material. Furthermore, each tumor type has its own nutrient and growth factor 
requirements. For example, several reports on breast cancer tissue slices used addition of 
insulin [61,68,71]. 
Figure 2: Main applications of different ex vivo model systems. An ex vivo model system should be 
chosen according to the purpose of the specific research. Each ex vivo model system has its own benefits and 
disadvantages, making one more applicable for a specific research endeavor than the others.
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It is not easy to evaluate the merits of each tumor tissue slice culture system, as different 
assays and quality standards have been used to characterize tissue quality at various time 
points (table 1). Most investigators report on tissue morphology and cell death, although 
careful quantification is sometimes lacking. However, proliferation is not always monitored 
over time or different methods were used to assess proliferation. Often proliferation rate is 
estimated using Ki67 staining and several tissue slicing publications use this same marker. 
However, this may not faithfully reflect the proliferative state at the time of assay, as Ki-67 
is expressed in all phases of the cell cycle, except G0 [74]. Therefore, proliferation should be 
evaluated with markers for S/G2 phase cells (geminin or cyclin A) or DNA synthesis (EdU 
incorporation), which measure active proliferation directly. 
 We propose a minimal standard, which should be performed for each tissue slice 
culture method, to enhance transparency and improve comparison between experiments 
and research groups. This standard should at least include morphology, proliferation and 
apoptosis of the tumor cells assessed up to 7 days of incubation. Moreover, it is of utmost 
importance to report all culture conditions used, instead of only those achieving optimal 
results. This should allow selection of the optimal culture system for organotypic tissue 
slices which can subsequently be adopted as the standard in the field of personalized 
medicine and drug testing.
Cancer-on-chip
New 3D culture systems incorporate advances in biomaterials, microfluidics, and tissue 
engineering to improve culture quality and reproducibility. Cancer-on-chip is a general 
term to describe various 3D microculture systems to maintain tumor cells in a controllable 
microenvironment. For example, cultivation of difficult-to-preserve primary patient-
derived multiple myeloma cells has been achieved in a device consisting of a 3D tissue 
scaffold constructed in a perfused microfluidic environment [75]. Recent progress in the 
cancer-on-chip field, specifically in hydrogel-incorporated microfluidics for long-term cell 
maintenance and exploitation of these culture devices for automated bioassay applications 
was reviewed by Lee et al [76]. Specific microfluidics devices have been designed to study 
metastasis formation as well as personalized immunotherapy [77,78]. 
 Up to date, most cancer-on-chip systems facilitate cultivation of tumor cells. Yet, 
organotypic tissue slices can be inserted into these microfluidic devices as well, enabling 
long-term culturing with decreased handling of tissue slices. The conditions in these 
devices can be very similar to in vivo conditions, with constant supply of nutrients, waste 
removal and controlled access to oxygen. Moreover, endothelial barriers and interstitial 
pressure can also be mimicked in the more elaborate versions of these cancer-on-chip set-
ups [79]. Thereby, the maximum time that slices remain vital in culture could be expanded 
and cultivation will be more high-throughput compared to original organotypic tissue 
slice cultures [80]. Optimization of the exact geometry and growth conditions of these 
microfluidics set ups hold great promise for tumor slice culturing and development of 
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predictive diagnostic assays. Although 3D microculture systems have been developed, 
this technique requires extensive optimization to achieve systems facilitating tissue slice 
cultivation. 
Conclusions and future prospects
Patient stratification is of utmost importance in the era of personalized medicine. Selection 
of patients for precision therapies should ideally be based on the tumor phenotype. 
Functional ex vivo assays may be the ultimate selection method when unique molecular 
markers have not been identified for particular drugs. 
 Approaches for patient stratification should be fast, simple and widely applicable 
to many tumor types or subtypes without being biased for cell selection and tumor 
heterogeneity. As generation time of organotypic tissue slices is very fast and results 
can be obtained within days, this model is in principle suitable for drug selection in 
the personalized medicine era, whereas 2D monolayers, 3D organoids and PDX models 
require longer generation times. On the other hand, organoids and 2D monolayers can be 
exploited for high-throughput drug screenings, yet tissue slices remain a low-throughput 
technique. This indicates that selecting the right model system for the right purpose is at 
least as important as developing new and improved culture systems (Figure 2). Therefore, 
a thorough understanding of the advantages and drawbacks of each culture method is 
important.
 In the future, developments in the field of cancer-on-chip might integrate the best 
of both worlds, incorporating tumor heterogeneity and tumor-stroma interactions 
represented in organotypic tissue slices in a more high-throughput fashion.
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Functional ex vivo assay reveals 
homologous recombination deficiency 
in breast cancer beyond 
BRCA gene defects
Abstract
Introduction Tumors of germline BRCA1/2 mutated carriers show homologous recombination (HR) 
deficiency (HRD), resulting in impaired DNA double strand break (DSB) repair and high sensitivity to 
Poly-(ADP-Ribose)-Polymerase (PARP) inhibitors. Although this therapy is expected to be effective 
beyond germline BRCA1/2 mutated carriers, a robust validated test to detect HRD tumors is lacking. 
In the present study we therefore evaluated a functional HR assay exploiting the formation of 
RAD51 foci in proliferating cells after ex vivo irradiation of fresh breast cancer (BrC) tissue: the REpair 
CAPacity (RECAP) test. 
Methods Fresh samples of 170 primary BrCs were analyzed using the RECAP test. The molecular 
explanation for the HRD phenotype was investigated by exploring BRCA deficiencies, mutational 
signatures, tumor infiltrating lymphocytes (TILs) and microsatellite instability (MSI). 
Results RECAP was completed successfully in 125 out of 170 samples (74%). Twenty-four tumors 
showed HRD (19%), whereas six tumors were HR intermediate (HRi) (5%). HRD was explained by 
BRCA deficiencies (mutations, promoter hypermethylation, deletions) in 16 cases, whereas seven 
HRD tumors were non-BRCA related. HRD tumors showed an increased incidence of high TIL counts 
(p=0.023) compared to HR proficient (HRP) tumors and MSI was more frequently observed in the 
HRD group (2/20, 10%) than expected in BrC (1%) (p=0.017). 
Conclusion RECAP is a robust functional HR assay detecting both BRCA1/2 deficient and BRCA1/2 
proficient HRD tumors. Functional assessment of HR in a pseudo-diagnostic setting is achievable 
and produces robust and interpretable results. 




Breast cancer (BrC) is the most common malignancy in women with the second highest 
cancer related mortality rate [1]. Approximately 3% of all BrC cases are due to germline 
mutations in BRCA1/2 [2], and in triple negative BrCs (TNBCs) this percentage is even 10-
20% [3]. The BRCA proteins play an important role in the homologous recombination (HR) 
pathway, the error-free DNA double strand break (DSB) repair pathway that operates 
during the S- and G2-phase of the cell cycle. HR deficiency (HRD) leading to impaired DNA 
DSB repair is frequently caused  by, but not limited to, defects in BRCA1/2 [4]. 
 Therapies specifically targeting tumor cells with impaired HR capacity are Poly ADP-
Ribose Polymerase (PARP)-inhibitors (PARPi), as well as classical chemotherapies such as 
platinum-derivates and alkylating agents [5]. PARPi causes persistence of single strand DNA 
breaks (SSBs) by trapping PARP1 on DNA, while platinum-derivates cause DNA interstrand 
crosslinks. Both types of lesions result in replication fork stalling and/or collapse, frequently 
leading to DSBs that need HR for their repair [5]. The targeted approach of PARPi kills tumor 
cells lacking HR, whereas normal cells remain unharmed, due to their normal DSB repair 
capacity, a phenomenon often referred to as synthetic lethality.  Recently FDA approval 
was granted for the use of Olaparib in germline BRCA mutated BrC based on the results of 
the Olympiad trial [6].
 Although evidence is emerging that the use of PARPi could be extended beyond 
germline BRCA1/2 mutated cancers to sporadic cancers with BRCA-like features, a gold 
standard test for predicting response to treatments targeting HR is not yet available [7]. 
Several different HRD tests exist, mostly based on genomic patterns or transcriptional 
predictors of BRCAness [8-12].
 These genomic tests measure the accumulation of mutations and chromosomal 
aberrations over time, but not necessarily reflect the real-time HR status. Beyond 
mutational status, several other factors influence tumor behavior and therapy response, 
such as epigenetic changes and the microenvironment of the tumor cells. Independent 
of the underlying cause, the downstream effect of HR impairment (phenotype) can be 
assessed functionally. A functional diagnostic assay therefore has the potential for more 
precisely detecting patients  who may benefit from PARPi than genomic assays. 
 A functional HRD assay was first described by Graeser et al, assessing RAD51 focus 
formation, a marker of HR competence, in tumor biopsies obtained 24 hours after in vivo 
anthracycline treatment [13]. This provided the first evidence that RAD51 focus formation can 
serve as a predictive biomarker. To enhance clinical utility of this biomarker, test outcomes 
should be available before start of treatment. Therefore, we developed the homologous 
REpair CAPacity (RECAP) test exploiting the formation of RAD51 foci in proliferating cells 
after ex vivo irradiation of fresh BrC tissue, providing a real-time HR status of the tumor [14]. 
The aim of the current study was to validate the RECAP test in an extensive cohort of 
primary BrCs and provide evidence that this functional test is achievable in a pseudo-
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clinical setting. Additionally, thorough molecular characterization of the HRD phenotype 
is performed, proving that HRD tumors encompass more than only BRCA deficiencies.  
Methods
Primary breast cancer specimens
Residual fresh BrC tissue was prospectively collected from lumpectomy of the breast or 
mastectomy specimens in the Erasmus MC Cancer Institute, Haven hospital and Maasstad 
hospital in Rotterdam, The Netherlands between 1 October 2011 and 1 September 2016. 
The first 41 patients were also included in our previous cohort [14]. After macroscopic 
evaluation of the surgical specimen by trained pathologists, residual tumor tissue was 
collected for our research purposes according to the “Code of proper secondary use of 
human tissue in the Netherlands” established by the Dutch Federation of Medical Scientific 
Societies and approved by the local Medical Ethical committees (MEC-11-098). Patients 
who had objected to secondary use of residual tumor material for research purposes were 
not included in this study. Patients with ductal carcinoma in situ (DCIS) only or patients 
receiving neo-adjuvant chemotherapy were excluded. 
RECAP test
Obtained tissue samples were immediately transferred into customized breast tissue 
culture medium, as described in Naipal et al [14]. Processing of samples was performed 
within 4 hours after the tissue was resected. Microscopic analysis of Hematoxylin and 
Eosin (HE) stained sections was performed to determine presence of invasive carcinoma. 
The RECAP test, a functional assay exploiting the formation of RAD51 foci in proliferating 
cells after ex vivo irradiation of fresh BrC tissue, was performed and results were analyzed 
as described previously [14]. In brief, presence of RAD51 foci was determined in S/G2 cells 
only, which stain positive for Geminin. At least 30 Geminin expressing cells were counted 
per tumor sample. A cell was considered RAD51 positive when at least 5 RAD51 foci could 
be detected. Based on previous experiments with patient derived xenograft (PDX) models 
with known BRCA status, tumors were classified as HR proficient (HRP), HR deficient (HRD) 
or intermediate (HRi) when more than 50%, less than 20% or between 20-50% of geminin 
positive cells showed ≥5 RAD51 foci, respectively. 
Workflow of molecular characterization of the HRD phenotype
To unravel the possible molecular mechanism underlying the HRD phenotype, several 
molecular tests were performed retrospectively (Figure 2 and Figure S1). As no DNA could 
be obtained for 1 HRD sample, we conducted the analyses for 23 HRD and 6 HRi samples. 
First, BRCA sequencing and BRCA1 promoter methylation analysis was performed in HRD 
and HRi samples, as well as in all TNBC (n=5), ER/PR- HER2+ (n=2) and 21 ER/PR+ HRP 
tumors (total n=28) (Figure S1). The HRD and HRi tumors without molecular explanation 
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for their phenotype were subjected to BRCA1 and BRCA2 MLPA analysis to identify large 
genomic rearrangements (LGRs), as LGRs are not usually identified by targeted sequencing. 
In addition to this targeted approach, morphological examination of TILs as well as Whole 
Exome Sequencing (WES) was performed on a selection of tumors to further explore 
molecular aspects connected to the HRD phenotype.
DNA isolation
Isolation of DNA from 30 µm fresh frozen tissue section samples was performed 
using the NucleoSpin Tissue Kit (Macherey-Nagel, Düren, Germany) according to the 
manufacturer’s instructions. Quantity and quality checks of isolated DNA were performed 
using the MultiNA microchip electrophoresis system (Shimadzu, ‘s Hertogenbosch, The 
Netherlands), Nanodrop 2000-v.1 (Thermo Fisher Scientific) and Qubit (Thermo Fisher 
Scientific). 
BRCA1/2 analyses 
Ion semiconductor sequencing on the Ion Torrent Personal S5XL was performed according 
to manufacturer’s instructions (Thermo Fisher Scientific). Adapter-ligated libraries were 
constructed using the AmpliSeq Library kit 2.0 with amplicons designed targeting BRCA1/2 
and TP53. Generation of sequence reads, trimming adapter sequences, filtering, and 
removal of poor signal-profile reads was performed via the Ion Torrent platform-specific 
pipeline software Torrent Suite v5.2.2. Initial variant calling was performed by comparison 
to the reference genome hg19 (build 37) using the “Torrent Variant Caller v5.2.0.34” 
plug-in from the Torrent Suite Software. All BRCA2 variants were validated by Sanger 
sequencing  and pathogenicity was evaluated using interactive Biosoftware Alamut 
Visual v.2.7.2. BRCA1 promoter methylation was analyzed as previously described [15]. 
Multiplex ligation-dependent probe amplification (MLPA) analysis of BRCA1 and BRCA2 
was undertaken to identify large rearrangements using the SALSA MLPA kit P002B, and for 
confirmation of observed abnormalities, the SALSA MLPA kit P087 was used (MRC Holland, 
Amsterdam, The Netherlands). Analyses were performed according to the manufacturer’s 
instruction; products were run on an ABI automated sequencer (ABI 3730XL), and the data 
were analyzed by Genemarker version 2.7.0 (Softgenetics, State College, PA).
In situ detection of BRCA1 RNA  
In situ detection of BRCA1 mRNA was performed using RNAScope (Advanced Cell 
Diagnostics, Newark, USA) on the automated Ventana Discovery Ultra system (Ventana 
Medical Systems, Roche, Tucson, USA). BRCA1 and positive control peptidylprolyl 
isomerase B (PPIB) probes (product codes: 485479 and 313909) were purchased from 
the same company. RNAscope analysis was performed according to manufacturer’s 
instructions using the reagent kit (VS Reagent Kit 320600; Advanced Cell Diagnostics) on 




DNA libraries for Illumina sequencing were generated using standard protocols (Illumina, 
San Diego, CA, USA) and subsequently sequenced in an Illumina HiSeq 2500 system by 
GATC-biotech (Konstanz, Germany). Exome-targeting was performed using the Sureselect 
v5 (v6 for tumors M077, M209, M211) methods using standard protocols (Agilent 
Technologies, Santa Clara, CA). DNA libraries were whole-exome sequenced (2x125bp) 
using the HiSeq v4 paired-end sequencing protocol to a minimum depth base coverage 
of 90x for tumor samples and 60x for matched normal. Sequence reads were mapped 
against human reference genome GRCh37 using Burrows–Wheeler Aligner (v0.7.12) 
with default settings [16]. Sequence reads originating from multiple lanes were merged 
after alignment using Samtools (v1.5) prior to further analysis [17]. Sequence duplicates 
were marked using PicardTools (v1.129) [18]. Somatic variant calling was performed by 
Mutect2 (v3.7) using a matched-normal design whilst utilizing the dbSNP (v149, hg19) 
and COSMIC (v80, hg19) databases and using default settings [19-21]. Variant annotation was 
performed by ANNOVAR [22]. Heuristic filtering removed variants not passing all standard 
Mutect2 post-calling filters. Sequence data has been deposited at the European Genome-
phenome Archive (EGA, http://www.ebi.ac.uk/ega/), which is hosted by the EBI, under 
accession number EGAD00001003929.
Mutational signatures 
For each somatic variant, its trinucleotide context was derived from the human reference 
genome GRCh37 and enumerated into a mutational spectrum matrix Mij (i = 96; number 
of trinucleotide contexts; j = number of samples) using the MutationalPatterns R package 
(v1.4.0) in the R statistical platform [23]. Multi-allelic and InDel variants were not included 
in this analysis. The thirty consensus mutational signatures, as established by Alexandrov 
et al., (matrix Sij; i = 96; number of trinucleotide motifs; j = number of signatures) were 
downloaded from COSMIC (as visited on 8-11-2017) [24]. Per sample, a constrained 
linear combination of the 30 validated mutational signatures was constructed, which 
reconstructs the sample-specific mutational spectrum, using non-negative least squares 
regression implemented in the R package pracma (v1.9.3). Signatures with lower relative 
contribution than 3% were summarized into a “Filtered” category.
MSI analysis, MMR protein IHC and MLH1 promotor methylation assay 
These analyses were performed as previously described [25]. 
Tumor infiltrating lymphocytes
Tumor infiltrating lymphocytes (TILs) were scored on HE stained sections, according to the 
consensus by the International TILs Working Group 2014 [26]. 




Statistical analyses were all 2-sided and performed using IBM SPSS statistics v21. 
Significance was calculated by Fisher’s exact test for categorical data, by Mann-Whitney 
test for continuous data and by exact binomial test for the incidence of MSI. P-values of 
<0.05 were considered significant.  
Results
Ex vivo functional RECAP test 
A total of 170 samples were subjected to the RECAP test (Figure S1) [14]. In 125 out of 
170 (74%) primary BrC tissues RECAP was completed successfully (Figure 1). In all cases, 
the reason for failure (n= 45) was lack of proliferating tumor cells. No differences in 
clinicopathologic characteristics between tumors that yielded successful versus non-
successful tests were observed (Table S1). The first 41 patients were also included in our 
previous cohort. Here, we show that execution of a functional assay in a pseudo-diagnostic 
setting is achievable and validate the findings from the earlier cohort (11% HRD in cohort 
1 versus 19% HRD in cohort 2, p=0.339). In total, we identified 95 (76%) HRP, 24 (19%) HRD 
and 6 (5%) HRi samples (Figure 1). Both HRi and HRD tumors were more frequently TN (p 
< 0.001) and Bloom and Richardson (B&R) grade 3 (p < 0.001) than HRP tumors. Also, HRD 
tumors had a larger size (p = 0.050) and were never B&R grade 1 (Table S2). 
Identification of BRCA defects in HRD breast cancers
Pathogenic BRCA2 mutations were found in six (6/23=26%) HRD samples, but not in the 
tested HRP samples (Table 1). In six tumors (2 HRD, 1 HRi and 3 HRP) BRCA2 variants were 
detected that were classified as benign. We did not identify any BRCA1 point mutations. 
Next, BRCA1 promoter hypermethylation was detected in 6 (6/23=26%) HRD tumors and 
in 1 HRi tumor, but not in tested HRP samples (Table 1). Interestingly, all 6 HRD tumors 
displaying BRCA1 promoter hypermethylation were TNBCs (Table 1 and Table S3). Vice 















































Figure 1: RECAP test results: 19% of primary breast cancers showed HRD. A) Schematic representation of 
the primary BrCs obtained for RECAP testing. B) Percentage of RAD51 foci positive tumor cells among geminin-
expressing nuclei in the 125 successful tests. 95 BrC samples were HRP (>50% Geminin positive cells with RAD51 
foci), 24 were HRD (<20% Geminin positive cells with RAD51 foci) and 6 samples were HRi (>20%/<50% Geminin 
positive cells with RAD51 foci). Black dots indicate TNBCs.
Thus, 12/23 HRD and 1/6 HRi samples were explained by a BRCA2 mutation or BRCA1 
promoter hypermethylation. Subsequently, we proceeded with an MLPA analysis for 
BRCA1 and BRCA2 on the sixteen HRD and HRi samples that remained unexplained to 
identify possible LGRs. Large BRCA1 deletions were found in four samples and BRCA2 
deletions in two samples (Table 1), of which one tumor harbored both a BRCA1 and BRCA2 
deletion. Two tumors (M248 (HRD) and M112 (HRi)) showed extensive chromosomal 
instability as they contained a mosaic BRCA1 deletion (meaning the deletion was present 
in a subclone of the tumor) as well as a BRCA2 duplication (Table 1). In total, BRCA defects 
have thus been identified in 16/23 HRD and 2/6 HRi samples.
 Silencing of BRCA1 was validated in tumors with BRCA1 promoter hypermethylation 
(n=7) and BRCA1 LGRs (n=4) by RNAscope in situ RNA hybridization (Figure S2 and Table 
1). All tumors displaying BRCA1 promoter hypermethylation showed absence of BRCA1 
RNA, except for two heterogeneous samples which contained BRCA1 positive as well 
as negative areas (Figure S2). As expected, the BRCA1 deletion in tumor M094 led to a 
total absence of BRCA1 mRNA (Figure S2). The mosaic BRCA1 deletions did not result in 
complete BRCA1 silencing (Figure S2). Neither did the BRCA1 deletion in M232, however 
this tumor also harbored a BRCA2 deletion that can explain the HRD phenotype. 
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After thorough analysis of the BRCA genes using several techniques, 13/23 HRD and 1/6 
HRi samples could be explained by deficiencies in BRCA. Moreover, 3/23 HRD (M131, M277 
and M248) and 1/6 HRi (M112) tumors also harbored BRCA deficiencies (BRCA1 promoter 
methylation or mosaic BRCA1 deletions), which explain the HRi and partially the HRD 
phenotype, as these tumors showed heterogeneous BRCA1 mRNA expression. Finally, 
7/23 HRD and 4/6 HRi tumors did not show any BRCA defects and therefore remained 
unexplained (Figure 2). To further characterize these HRD tumors, functional features 
correlating with the HRD phenotype were determined.
HRD tumors show more tumor infiltrating lymphocytes than HRP tumors
Recently, a subgroup of TNBC patients was identified who showed good response to 
immune checkpoint inhibition through Programmed Death-ligand 1 (PD-L1) blockade [27,28]. 
This subgroup was characterized by having >10% tumor infiltrating lymphocytes (TILs) 
and high CD8 lymphocyte counts in the tumor centers [28]. Since 11/17 TNBCs in our study 
showed HRD, we hypothesized that the RECAP test might select for a specific subgroup 
of TNBC patients who might benefit from PD-L1 therapy. We found that significantly 
more HRD tumors (6/22) had >10% TILs than HRP tumors (0/28) (p=0.004) (Figure 3). Also, 
tumors with BRCA defects showed more frequently >10% TILs compared to non-BRCA 
tumors (p=0.001), which was also true for TNBCs compared to ER/PR+ tumors (p=0.026).
HRD tumors show mutational signatures related to BRCA deficiencies and microsa-
tellite instability
Next, Whole Exome Sequencing (WES) was performed to determine the molecular 
landscape of HRD tumors. A selection of HRD (n=8) and HRi (n=3) tumors with BRCA1/2 
mutations/deletions, BRCA1 promoter hypermethylation and BRCA WT tumors as well 
as 1 HRP tumor were subjected to WES. First, mutational load was determined in these 
tumors and high mutational load did not correlate with high numbers of TILs. Second, 
we did not identify commonly mutated genes other than BRCA1/2, that might explain the 
functional HR defect. Third, WES data were used to identify mutational signatures which 
are specific combinations of mutations that arise due to a certain underlying mutational 
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Figure 3: HRD tumors more frequently showed >10% tumor infiltrating lymphocytes than HRP tumors.
A) HE sections were scored for stromal tumor infiltrating lymphocytes (TILs). Examples of samples with <1%, 
15% and 70% TILs are shown respectively. B) More HRD tumors (6/22) had >10% TILs than HRP tumors (0/28) 
(P=0.004). Also, tumors with BRCA defects showed more frequently >10% TILs compared to non-BRCA tumors 
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BRCA mutational signature 
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Not performed
Figure 2: Characteristics of HRD and HRi tumors. Overview of molecular alterations and TIL counts in each 
HRD or HRi tumor (NB, data for one HRD tumor is absent, because DNA was unavailable). LGR = large genomic 
rearrangements, MSI = microsatellite instability, TILs = tumor infiltrating lymphocytes in tumor stroma, ER = 
estrogen receptor. High TILs were defined as >10% TILs.
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Figure 4: HRD and HRi tumors showed mutational signatures related to BRCA as well as microsatellite
instability. Relative and absolute contribution of the mutational signatures in WES datasets is depicted,
as well as total numbers of single-nucleotide mutations and percentage of TILs in the sample.
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Mutational signatures were derived from the WES data from HRD/HRi tumors of which 
matching normal DNA was available to filter out germline variants (n=10) to explore novel 
mechanisms related to or underlying the HRD phenotype. Since discussion in the field 
exists that mutational signatures can only be faithfully obtained from whole genome 
sequencing (WGS) instead of WES data, we first carried out a pilot experiment comparing 
mutational signature analysis using all somatic mutations in 5 BrC WGS datasets [30] and 
filtered these WGS datasets to only contain somatic mutations on exonic regions. Both 
methods resulted in similar distributions of the mutational signatures (Figure S3).
 Mutational signature 3 is related to failure of DSB repair by HR and associated with 
germline and somatic BRCA1/2 defects in breast, pancreatic, and ovarian cancers [31]. 
Signature 3 was present in 6/10 analyzed samples (M94, M95, M119, M131, M141, and 
M221) (Figure 4). APOBEC related mutagenesis (predominantly C>G or C>T substitutions 
in TCA or TCT motifs) is captured in signatures 2 and 13, which arise through activity of the 
AID/APOBEC family. BRCA related signatures could also be identified to a lesser extent in 
samples (M211 and M094) having a high mutational burden of signatures 2 and 13. 
B
M077












Figure 5: Two HRD breast tumors showed microsatellite instability. A) MSI was found in two HRD tumors, but 
not in any HRP or HRi tumors. B) Immunohistochemical staining of MLH1, PMS2, MSH2 and MSH6.
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Microsatellite instability in HRD breast cancers 
One tumor (M077) showed a high mutational load as well as high contributions of 
signatures 15, 20 and 26, which are related to microsatellite instability (MSI) and mismatch 
repair (MMR) deficiency  (http://cancer.sanger.ac.uk/cosmic/signatures). MSI is a 
common feature in endometrial and gastro-intestinal cancers, caused by either germline 
(Lynch syndrome) or somatic mutations in one of the MMR genes and/or promoter 
hypermethylation [32,33]. Presence of MSI in tumor M077 was confirmed using pentaplex 
PCR and immunohistochemistry for the MMR proteins, which showed absence of MLH1 
and PMS2, caused by MLH1 promoter methylation (Figure S4).
 A set of 44 tumors (20 HRD, 6 HRi, 18 HRP) was subjected to MSI analysis by pentaplex 
PCR and immunohistochemistry for the MMR proteins. One HRD tumor (M188) of which 
mutational signatures were not available, also showed MSI. MSI was never detected in 
any HRP tumors (Figure 5). Tumor M188 showed absence of MSH2 and MSH6, caused by 
a homozygous deletion of MSH2 (Figure S4). The two MSI BrCs (M077 and M188) were TN 
and BRCA WT and ER positive and BRCA2 mutated, respectively (Figure 2). The incidence 
of MSI within the HRD group (2/20, 10%) is significantly higher than the incidence of MSI 
in the unselected BrC population (1%) (p=0.017) [34,35]. 
Discussion
Here, a unique series of fresh primary BrC tissues (n=125) has been analyzed for HRD 
using the functional RECAP test. This first large validation study, describes that functional 
assessment of HR in a pseudo-diagnostic setting is achievable and produces robust 
and interpretable results for most patients (74%). We found that the percentage of HRD 
tumors detected by the RECAP test is similar in this larger cohort, as compared with 
our previous report. Therefore, both cohorts were combined to achieve more power to 
thoroughly investigate the molecular mechanism underlying the HRD phenotype. Sixteen 
HRD samples showed deficiencies in BRCA1/2 (BRCA mutations, deletions or promoter 
hypermethylation), whereas seven HRD tumors were non-BRCA related, demonstrating 
that HRD tumors encompass more than only BRCA deficient tumors. 
 Several different HRD tests have been designed to identify HRD tumors in addition to 
the BRCA mutated or promoter methylated tumors to enlarge the population of BrC patients 
that could benefit from treatments targeting the HR pathway. For example, the BRCAness 
classifier, which is based on specific genomic patterns derived from copy number data of 
BRCA1/2 mutated BrCs that also occur in sporadic cancers [10,11] and the Myriad MyChoice 
HRD test, which is a combined score of three different structural chromosomal aberrations 
(telomeric allelic imbalance (TAI), large-scale transition (LST) and loss of heterozygosity 
(LOH)) [36]. Both the BRCAness classifier and MyChoice are robust, easily applicable in the 
clinic and have also been validated to predict in vivo response to high dose chemotherapy 
and neo-adjuvant platinum based therapy, respectively, in TNBC patients [37,38]. As opposed 
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to the neo-adjuvant setting, the MyChoice HRD test did not predict response to PARPi 
therapy in platinum-sensitive recurrent ovarian cancer [39]. These genomic HRD tests have 
the drawback that they do not determine the real-time HR status, also it remains unclear 
whether all HRD cases are identified. In theory, the functional RECAP test can also detect 
reversion of the HRD phenotype in BRCA deficient tumors, that have been treated with 
various DNA damaging chemotherapies that may have induced resistance. Moreover, 
the BRCAness classifier focusses on TNBC only, whereas the RECAP test identifies HRD 
independent of hormonal status. More recently, a HRD test based on several genomic 
signatures has been published, HRDetect [40]. This test has recently been shown to 
predict in vivo response to platinum-based therapies in advanced breast cancer [41]. 
HRDetect relies on whole genome sequencing and is therefore more expensive and 
has a longer turnaround time for biopsy results, hampering its clinical implementation. 
Furthermore, the tumor cell percentage needs to be above 50% for reliable results, which 
is not a prerequisite for the RECAP test. On the other hand, HRDetect has the advantage 
that it can be performed on frozen material, whereas the RECAP test requires fresh 
material. The percentage of non-BRCA HRD tumors (approximately 33%) detected by the 
HRDetect and the RECAP test are quite comparable, although it remains elusive whether 
these tests identify the same tumors, therefore comparison of several HRD tests within the 
same patient cohort is required.
 The major strength of the current study is that functional diagnostics have been 
applied to a unprecedented large collection of tumors. The advantage of the RECAP 
test over genetic tests, is its functional character for exploring the HR phenotype rather 
than the static nature of genomic tests. Also, the RECAP test is feasible in samples with 
low tumor percentage, since the microscopic read-out allows differentiation between 
tumor and stromal cells. The RECAP test has a high success rate and results are available 
within one week after the biopsy procedure. In this study, reproducibility and robustness 
of the RECAP test is validated in an independent set of 129 tumors. For the molecular 
analyses to unravel the mechanisms underlying the HRD phenotype, the 41 samples 
included in our previous publication were also included, to achieve more power. The 
main limitation of this study is that although prospective trials evaluating the predictive 
value of RECAP for in vivo patient response to PARPi have been initiated, results are not yet 
available. However, previously a functional RAD51 test performed on biopsies obtained 
from patients 24 hours after start of therapy correlated with response to anthracycline 
based therapies, indicating that functional assessment of HR can have predictive value for 
therapy response [13]. 
 Among the spectrum of BRCA defects, we have not identified any BRCA1 mutations. 
This is somewhat remarkable but could be due to a selection bias, as the Erasmus Medical 
Center is specialized in hereditary BrC and all patients with TNBC are tested, therefore most 
families with hereditary BRCA1 mutations have been identified and carriers are offered 
strict screening programs or undergo prophylactic surgery in The Netherlands [42]. Also, in 
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this study there is a selection bias for tumor size, as the tumor should be large enough to 
provide residual material without compromising standard diagnostic procedures. Since 
BRCA mutation carriers are offered strict screening programs, tumors are often identified 
at an early stage and residual material is not available for the RECAP test. Also, many BRCA1 
mutation carriers with TNBC are treated with neoadjuvant chemotherapy, which was an 
exclusion criterion for this study. 
 Clinical consequences of BRCA1 promoter methylation are unclear [43]. In the current 
study, BRCA1 promoter methylation resulted in absence of BRCA1 RNA in four samples, 
but in two tumors there was still heterogeneous expression of BRCA1 RNA (Figure S2). 
In these tumors, the percentage of cells with RAD51 foci was 1% and 2%, respectively. 
The discrepancy between the very low HRD score and heterogeneous BRCA1 RNA could 
be explained by sampling from different areas of the tumor, since the tumor sample for 
the RECAP test was irradiated and an unirradiated tumor sample was used for molecular 
analyses. This sampling error is not limited to this study, but also occurs in regular 
diagnostics when biopsies are obtained from a certain region of a heterogeneous tumor. 
Tumor heterogeneity in BRCA1 promoter methylated tumors is very important for clinical 
decisions on PARPi use. If subsequent studies reveal that this phenomenon is observed 
in a large fraction of these tumors, PARPi may not be very effective in tumors with BRCA1 
promoter methylation.
 We identified 6 HRi BrCs in the current cohort. Only in one of the HRi tumors, distinct 
areas of RAD51 negative and RAD51 positive tumor cells were observed, suggesting 
clonal heterogeneity. The other HRi tumors all showed interspersed RAD51 negative as 
well as RAD51 positive tumor cells. As a BRCA defect was found in 2/6 HRi tumors, they 
biologically resemble HRD tumors. However, whether HRi tumors benefit from PARPi 
treatment remains to be elucidated. 
 Mutational signature analyses were performed to explore novel mechanisms related 
to or underlying the HRD phenotype. One HRD tumor that showed a large contribution 
of three signatures related to MSI and MMR deficiency, proved to be truly MSI. Using 
pentaplex PCR and immunohistochemistry, MSI was discovered in two HRD (2/20, 10%) 
but not in HRP or HRi tumors. This incidence is much higher than in the unselected BrC 
population (1%) [34,35], suggesting that the RECAP test may also identify MSI tumors. 
The relation between MSI and HRD as well as the order in which tumors develop these 
deficiencies remains unclear and future research is required. We hypothesize that either 
MSI tumors acquire HRD over time due to accumulation of mutations in genes involved in 
HR [44], or HRD tumors acquire MSI at a later stage of tumor development as a compensatory 
mechanism, to lower replication fork instability by not repairing mismatches but rather 
continuing DNA replication.  As MSI tumors have many neo-antigens, PD-L1 blockade 
therapy showed anti-tumor activity in phase I trials [45]. Recently, a first report of a patient 
with MSI BrC showing a profound response to PD-L1 blockade was published [46]. Moreover, 
tumors with high numbers of TILs are generally more sensitive to immunotherapy [47]. 
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Interestingly, in our cohort, the two MSI tumors comprise a different subset of HRD tumors 
than the ones with high TILs. Thus, the RECAP test identifies not only tumors with BRCA 
defects (n=16), but also a subgroup of BrCs that might respond well to immunotherapy 
due to either MSI (n=2) or high TIL counts (n=6). 
 The RECAP test is a robust functional HR assay detecting both BRCA1/2 deficient and 
BRCA1/2 proficient HRD tumors. Functional assessment of HR in a pseudo-diagnostic 
setting is achievable and produces robust and interpretable results. Clinical trials 
evaluating the predictive value of the RECAP test for in vivo response to PARPi have been 
initiated.
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Supplementary Table 1: Comparison of clinicopathologic characteristics between successful 
tests and not successful tests.
Successful test Not successful test P-value
Tumor size






























2 (4.4%) P = 0.160
Total 125 45
*independent of ER/PR status. Significance was calculated by Fisher’s exact test for categorical 
data and by Mann-Whitney test for continuous data (tumor size).
Supplementary Table 2: Comparison of clinicopathologic characteristics RECAP positive/
negative/intermediate tumors.











































11 (45.8%) P = 0.014 P < 0.001
Total 95 6 24
*independent of ER/PR status. Significance was calculated by Fisher’s exact test for categorical 
data and by Mann-Whitney test for continuous data (tumor size).  
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P001* metaplastic neg neg neg 3 5.5 negative 1
P002* ductal/lobular pos pos neg 3 4.8 negative 1
P003* ductal pos pos neg 3 3 positive 88
P005* ductal pos neg neg 2 2.5 NA  
P008* ductal pos neg neg 3 2.2 NA
P009* ductal pos pos neg 1 1.5 positive 75
P012* ductal neg neg pos 3 5.1 NA  
M002* ductal pos neg pos 2 3.2 NA  
M003* lobular pos neg neg 2 2.8 NA  
M005* ductal pos neg neg 1 5.5 NA  
M007* ductal pos pos neg 3 2.6 NA  
M009* lobular pos pos neg 2 2.8 positive 71
M018* ductal pos pos neg 3 12.5 positive 71
M019* lobular pos pos neg 3 8.2 positive 77
M021* ductal neg neg pos 3 2.4 positive 67
M022* ductal pos pos neg 1 1.6 positive 81
M023* ductal pos pos neg 3 3.4 positive 89
M025* ductal pos pos neg 2 1.7 positive 67
M026* ductal pos pos neg 2 4.5 NA
M028* ductal neg neg neg 3 4.8 negative 3
M029* ductal pos pos pos 3 3.5 positive 62
M030* ductal pos pos neg 2 10 positive 67
M031* ductal pos pos neg 2 2.1 NA
M043* ductal pos neg neg 3 4.3 positive 75
M046* ductal neg neg pos 3 2.3 positive 70
M047* ductal pos pos neg 3 2.5 NA  
M048* lobular pos neg neg 3 5.8 positive 86
M051* ductal pos pos neg 3 2.7 positive 75
M052* ductal pos pos neg 3 7.5 positive 71
M055* ductal pos pos neg 3 5.4 intermediate 38
M056* ductal pos neg neg 3 2.9 positive 74
M057* ductal neg neg neg 3 2.2 negative 13
M058* ductal pos pos neg 3 2.6 positive 79
M059* ductal pos neg neg 2 3.4 positive 84
M060* ductal pos pos neg 2 2.2 positive 84
M061* ductal pos pos neg 2 1.4 NA
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M062* ductal neg neg neg 3 3.4 positive 83
M063* ductal pos pos neg 2 1.4 positive 71
M064* ductal pos pos neg 2 3.4 NA  
M065* ductal pos pos pos 3 2.1 positive 57
M066* ductal pos neg neg 1 1.8 NA
M067* lobular pos pos neg 2 1.3 positive 74
M068* ductal pos pos neg 1 1.5 NA
M069* ductal pos pos neg 3 1.9 NA  
M070* lobular pos pos neg 2 4 NA
M071* lobular pos pos neg 2 5.5 positive 75
M072* ductal pos pos neg 2.00 11.00 positive 74
M073* lobular pos pos neg 2.00 1.80 NA
M074* ductal pos pos neg 2.00 10.50 positive 77
M075* ductal pos pos neg 3 10.00 NA
M077 ductal neg neg neg 3 2.30 low/negative 0.5
M078 ductal pos pos neg 3 2.50 positive 53
M079 ductal pos pos neg 2 1.50 NA
M080 ductal pos pos neg 3 2.10 positive 85
M082 micro papillary pos pos neg 2 6.50 NA  
M083 ductal pos pos neg 2 6.50 positive 62
M084 lobular pos pos neg 2 2.50 positive 65
M086 ductal pos pos neg 1 1.40 NA
M088 ductal pos neg neg 2 3.8 NA
M089 ductal pos pos neg 3 3.8 positive 82
M090 ductal pos neg neg 3 3.4 positive 85
M092 ductal pos neg neg 2 9 NA
M093 lobular pos pos neg 2 2.5 low/negative 8
M094 ductal pos neg pos 2 1.7 low/negative 8
M096 ductal pos pos neg 3 2.8 low/negative 4
M097 ductal pos pos neg 3 2.6 NA
M098 ductal pos pos neg 1 1.9 NA
M099 ductal pos pos neg 1 1 NA
M100 ductal neg neg neg 3 2.5 positive 97
M101 ductal neg neg neg 3 1.6 NA
M102 lobular pos pos neg 3 7 NA
M104 ductal pos pos neg 3 1.3 positive 90
M106 ductal neg neg pos 3 2.6 low/negative 6
M107 ductal pos pos neg 2 1.4 NA
M108 ductal pos pos neg 2 2.6 positive 80
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M109 ductal pos pos neg 1 2.5 positive 94
M110 lobular pos pos neg 1 2.9 positive 94
M111 ductal pos pos pos 1 3.5 positive 90
M112 ductal pos pos pos 3 3.5 different 30
M113 ductal pos neg neg 2 1.2 positive 55
M114 lobular pos neg neg 2 3 positive 78
M115 ductal pos pos neg 2 1.8 positive 51
M116 ductal pos pos neg 2 3.8 NA  
M117 ductal pos pos neg 3 1.8 positive 67
M118 ductal pos pos neg 3 1.7 NA
M119 ductal neg neg neg 3 7 low/negative 0.5
M120 ductal pos pos neg 2 3 positive 59
M121 lobular pos neg neg 2 9.7 positive 86
M125 ductal pos pos neg 3 2.6 positive 66
M128 ductal pos neg pos 3 1.4 positive 67
M129 ductal pos pos neg 1 1.6 positive 91
M130 ductal pos pos neg 3 2.5 NA  
M131 ductal neg neg neg 3 5.5 low/negative 1
M133 ductal pos pos neg 2 5.5 positive 84
M135 ductal pos pos neg 3 5.5 positive 95
M136 ductal neg neg neg 3 2.3 low/negative 5
M141 ductal pos neg neg 3 2.5 intermediate 28
M142 ductal pos neg pos 2 3.2 positive 80
M143 ductal pos pos neg 3 2.7 positive 96
M144 ductal neg neg neg 3 2.2 NA  
M146 ductal pos pos neg 2 1.9 positive 58
M147 ductal pos pos neg 2 2.2 NA  
M148 ductal pos pos neg 3 2.5 NA  
M149 ductal pos pos pos 3 2.6 positive 53
M150 ductal pos pos neg 2 1.3 positive 92
M152 ductal pos pos neg 2 5.5 NA
M153 ductal pos pos neg 3 4 positive 95
M155 lobular pos neg neg 2 1.8 positive 65
M156 ductal pos pos neg 2 2.5 negative 5
M157 ductal pos pos neg 1 1.4 positive 88
M159 ductal pos pos neg 2 3 positive 95
M162 ductal pos pos neg 1 1.5 positive 93
M163 ductal pos pos neg 2 2.2 NA
M164 ductal pos pos neg 2 2.5 positive 88
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M166 ductal pos pos neg 3 3 positive 92
M169 ductal pos pos neg 3 4 positive 66
M170 ductal pos pos neg 3 4.5 positive 51
M171 ductal pos pos pos 3 7.5 positive 63
M175 ductal pos pos neg 2 1.1 NA  
M176 ductal pos pos neg 2 4.4 NA  
M178 ductal pos pos pos 2 1.7 NA
M179 ductal pos pos neg 1 2.2 positive 75
M180 ductal pos neg neg 2 2.2 positive 71
M181 ductal neg neg neg 3 5.5 positive 78
M182 ductal neg neg neg 3 1.9 negative 2
M183 ductal pos pos neg 2 1.3 positive 66
M187 ductal pos pos neg 2 3.2 positive 96
M188 ductal pos pos neg 3 12.1 negative 1
M191 lobular pos pos neg 2 3 NA  
M193 ductal pos pos neg 3 1.2 positive 82
M195 lobular pos neg neg 2 2.4 positive 82
M197 mucineus pos pos neg 2 2 positive 91
M198 ductal pos neg neg 2 2.8 NA  
M199 ductal pos neg pos 1 7 positive 72
M200 ductal pos pos neg 3 3.5 positive 89
M201 lobular pos pos neg 2 4.5 positive 94
M204 ductal pos pos neg 2 2.6 NA  
M205 lobular pos pos neg 2 5.1 positive 88
M208 ductal pos neg pos 2 2.2 positive 79
M209 ductal neg neg pos 3 2.8 intermediate 25
M210 lobular pos neg neg 3 1.2 positive 86
M211 ductal neg neg pos 3 4 negative 0
M213 ductal neg neg neg 2 2.9 positive 86
M217 ductal pos neg neg 3 7 positive 91
M218 ductal pos pos neg 2 1.2 positive 95
M225 ductal pos pos neg 2 2.8 positive 95
M229 ductal pos pos neg 1 4.5 positive 100
M231 ductal pos neg neg 3 2.2 negative 2
M232 ductal pos neg neg 3 3.2 negative 0
M233 lobular pos pos neg 2 1.1 positive 94
M237 lobular pos pos pos 3 3.5 positive 95
M239 ductal pos pos neg 1 1 positive 85
M244 lobular pos pos neg 2 2.5 positive 82
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M247 ductal pos pos neg 2 4.5 positive 90
M248 ductal neg neg neg 3 3.5 negative 0
M253 ductal neg neg neg 3 4 intermediate 26
m255 ductal neg neg pos 3 6.5 NA  
M258 ductal pos pos neg 2 4.1 positive 100
M259 ductal pos pos neg 2 2.6 positive 92
M260 ductal pos pos neg 3 8.5 negative 10
M262 lobular pos pos neg 2 1.4 positive 99
M263 ductal neg pos neg 2 1.4 NA  
M264 ductal pos neg neg 1 1.2 positive 92
M266 ductal pos pos neg 2 2.4 positive 98
M269 lobular pos pos neg 2 3.8 positive 92
M270 ductal neg neg neg 3 3 negative 0
M271 lobular pos neg neg 2 7.5 negative 17
M275 lobular pos neg neg 2 2.7 negative 3
M277 pappilair neg neg neg 3 3.8 negative 2
M278 ductal pos pos pos 3 2.4 intermediate 37









Targeted BRCA1/2 sequencing    (HRD: n=23, HRi: n=6, HRP: n=28)
BRCA1 promotor hypermethylation   (HRD: n=23, HRi: n=6, HRP: n=28)
BRCA1/2 Large genomic rearrangements (LGRs) (HRD: n=11, HRi: n=4)
MSI analysis      (HRD: n=20, HRi: n=6, HRP: n=18)






TILs analysis      (HRD: n=22, HRi: n=6, HRP: n=28)
Sample size
Supplemental Figure 1: Workflow of functional RECAP test and molecular analyses. Fresh 
primary breast tumor specimens were collected and irradiated with 5 Gy, incubated for 2 hours 
before formalin fixation and paraffin embedding. Immunofluorescence with RAD51 and Geminin 
antibodies was carried out on paraffin sections. Molecular analyses were all performed on an 
unirradiated sample from the same tumor.
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Supplemental Figure 2: BRCA1 promoter hypermethylation and RNA in situ hybridization by 
RNAscope. M248, M253, M112 and M232 clearly showed presence of BRCA1 RNA, whereas in M94 
(BRCA1 deletion) no BRCA1 RNA was present. M131 and M277 showed heterogeneous presence of 





































































































































































Supplemental Figure 3: Comparison of mutational signature analysis using all WGS-derived 
somatic mutations versus using somatic mutations present on SureSelect v5 target regions only.
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Supplemental Figure 4: Microsatellite instability. Pentaplex PCR showed presence of MSI in M77 
and M188.
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Direct ex vivo observation of 
homologous recombination defect 
reversal after DNA damaging 
chemotherapy in metastatic breast 
cancer patients
Abstract
Background Biomarkers predicting response to Poly-[ADP-Ribose]-Polymerase inhibitors (PARPi) 
are required to detect PARPi sensitivity beyond germline BRCA mutated (gBRCAm) cancers and 
PARPi resistance among reverted gBRCAm cancers. Therefore, we previously developed the REpair 
CAPacity (RECAP) test, a functional homologous recombination (HR) assay exploiting the formation 
of RAD51 foci in proliferating cells after ex vivo irradiation of fresh primary breast cancer (BrC) tissue. 
The aim of the current study was to validate feasibility of this test on histological biopsies from 
metastatic BrC and to explore the utility of the RECAP test as a predictive tool for treatment with 
DNA damaging agents, such as PARPi. 
Methods Fresh tissue biopsies from easily accessible metastatic lesions from patients with locally 
advanced or metastatic BrC  were irradiated with 5 Gy and cultured for 2 hours, followed by detection 
of RAD51 foci presence (HR proficient) or absence (HR deficient). HR deficient (HRD) biopsies as well 
as platinum/PARP resistant biopsies were subjected to BRCA1/2 sequencing. 
Results RECAP has a success rate of 93% on biopsies from metastatic BrC lesions (n=44). While HRD 
was detected in 13 out of 41 biopsies (32%), only five showed a gBRCAm. In three gBRCAm patients, 
post-treatment RECAP tests showed HR phenotype reversion after in vivo progressive disease on 
platinum/PARPi treatment, which was explained in one patient by a secondary BRCA1 mutation. 
Conclusion The RECAP test, which reflects real-time HR status regardless of BRCA mutations, is 
feasible in metastatic BrC biopsies. Compared with gBRCA analysis, it may identify twice as many 
candidates for PARPi treatment.
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Introduction
Tumors developed among germline BRCA1/2 mutation (gBRCAm) carriers have a defect 
in homologous recombination (HR) and are therefore highly sensitive to Poly-[ADP-
Ribose]-Polymerase inhibitors (PARPi) and DNA double strand break (DSB) inducing 
chemotherapies [1-4]. Recently, FDA approval was obtained for the use of Olaparib in 
advanced gBRCAm breast cancer (BrC) [3].
 Until now,  gBRCAm status is the only predictive biomarker for response to PARPi 
therapy. However, evidence is emerging that PARPi are also effective in cancers with HR 
deficiency (HRD) caused by other mechanisms than gBRCAm, such as somatic BRCA1/2 
mutations or mutations of other HR genes [5]. Several different HRD tests have been 
designed to identify HRD tumors in addition to gBRCAm tumors to enlarge the population 
of BrC patients that could benefit from treatments targeting the HR pathway [6-10]. 
However, a gold standard test for predicting response to PARPi therapy is not yet available. 
Most HRD tests are based on specific genomic or transcriptomic patterns derived from 
gBRCAm tumors, which also occur in sporadic cancers (BRCAness) [6-10]. These tests 
measure the accumulation of mutations and chromosomal aberrations over time, thus 
they do not necessarily reflect the real-time HR status of the tumor. This poses a problem 
for the metastatic setting, as the HR status can change over time, e.g. as a result of 
selective pressure from chemotherapy [11]. Therefore, a functional diagnostic assay on 
tumor material has the potential of more precisely detecting patients who may benefit 
from PARPi treatment than germline mutation analysis only.
 The REpair CAPacity (RECAP) test, a functional HR assay exploiting the formation of 
RAD51 foci in proliferating cells after ex vivo irradiation of fresh BrC tissue, was previously 
developed for primary BrC (n=148) [12,13]. In the current study, we aimed to show feasibility 
of this test on biopsies from metastatic BrC lesions to enhance the diagnostic potential and 
clinical applicability of the RECAP test. Next, we aimed to find a molecular explanation for 
the observed HRD phenotype and we explored the utility of the RECAP test as a predictive 
tool for treatment with DSB inducing agents, such as PARPi, in this setting.
Materials and Methods
Biopsies
Patients with locally advanced or metastatic BrC, with metastatic lesions amenable 
for biopsies, who were planned to start systemic treatment were eligible. Therefore, 
patients with pulmonary and/or bone metastasis only were excluded due to risk of 
pneumothorax and technical difficulties with experimental procedures caused by 
calcifications (Supplemental table 3). Patients should have bilirubin <1.5 ULN and both 
AST and ALT <5x ULN in case of a liver biopsy. Platelets should be >100 x 10e9/L and INR 
<1.5, unless platelet/INR values were not necessary according to local protocols or after 
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consent of the intervention radiologist for that particular site of biopsy (e.g. biopsy of the 
breast). After registration and written informed consent each patient was scheduled for a 
biopsy, performed by a (intervention) radiologist according to local protocols. For distant 
metastases a core needle biopsy with a minimum of 18 Gauge and maximum of 12 Gauge 
was performed under imaging guidance. Biopsies from superficial metastases were 
performed using a standard 4 mm biopsy puncher. The study (NL49306.078.14/MEC14-
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Figure 1: RECAP test has a high success rate (93%) when performed on small biopsies. A: The RECAP test 
could be performed successfully in 41 out of the 44 biopsies of metastatic lesions (93%). We identified 13 HRD 
biopsies, 2 HR intermediate (HRi) and 26 HR proficient (HRP) biopsies. B: Characteristics of RECAP biopsies.
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RECAP test
Tumor samples were immediately transferred into customized breast tissue culture 
medium, as described previously [13], and processed within 4 hours after tissue resection. 
After irradiation and 2 hours of incubation, tissue was formalin fixed and paraffin 
embedded. Microscopic analysis of Hematoxylin and Eosin (HE) stained sections was 
performed to determine presence of invasive carcinoma. The RECAP test was performed 
and results were analyzed as described previously (Supplemental Figure 1) [13]. In brief, 
presence of RAD51 foci was determined in Geminin (GMN) positive, thus actively 
proliferating (S/G2), cells only. At least 30 GMN expressing cells were counted per tumor 
sample. A cell was considered RAD51 positive when at least 5 RAD51 foci were detected. 
Tumors were classified as HR proficient (HRP), HR deficient (HRD) or intermediate (HRi) 
when more than 50%, less than 20% or 20-50% of GMN positive cells showed ≥5 RAD51 
foci, respectively. 
BRCA1/2 analyses and RAD51 assay on cell lines
See supplementary methods.
Statistical analysis 
The aim of the study was to show feasibility of the RECAP test on biopsies from metastatic 
BrC. The primary endpoint was the proportion of metastatic BrC patients with a successful 
RECAP test result. A successful test was defined as the ability to classify the tumor as HRP, 
HRi or HRD. A representative biopsy was defined as a biopsy upon which a pathologist is 
able to set the diagnosis of metastatic breast malignancy. We decided that further research 
is warranted if the proportion of successful tests is higher than 80% and that the test does 
not have clinical value if this proportion is lower than 60% (Optimal Simon 2-stage design, 
α=0.1, β=0.1). According to these parameters, the required sample size was 38, with one 
interim analysis planned after inclusion of the 11th patient. In case ≤ 6 patients would have 
a successful test at the interim analysis, the study would be discontinued. Since it was 
expected that 10% of obtained biopsies would not be representative, a total of 43 patients 
were to be included. Differences between patients with successful and unsuccessful test 
were studied using the Chi-squared or Fisher’s exact test for categorical data. Statistical 
analyses were all 2-sided and were performed using IBM SPSS statistics v21, where 
p-values of <0.05 were considered significant.
 
Results
The RECAP test has a high success rate
A total of 51 patients met the inclusion criteria and were enrolled between February 
2015 and April 2017. In 6 patients no biopsy was obtained due to various reasons. One 
patient was excluded since pathological assessment of the biopsy revealed that it was a 
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metastasis of a neuroendocrine carcinoma (NEC) instead of BrC. Both NEC and BrC were 
diagnosed before in this patient. In total, 47 biopsies were obtained from 44 patients, of 
which 3 did not contain tumor cells, resulting in 44 representative biopsies. 












































































Figure 2: HRD tumor lesions became HRP after treatment with DSB inducing agents. A: Timelines of 
gBRCAm patients who developed reversal of the HR phenotype. B: Representative images of RAD51 stainings of 
pre- and post-treatment biopsies.
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The RECAP test could be performed successfully in 41 of the 44 biopsies of metastatic 
lesions (93%, 95% CI: 86% - 100%, p<0.001) (Figure 1A). Due to swift inclusion, slightly 
more patients were included than initially planned. Analysis of only the first 38 patients 
led to a similar conclusion. The reason for not successful testing in three biopsies was 
an insufficient number of proliferating (i.e. GMN positive) tumor cells (less than 30 GMN 
positive nuclei in M189, M250 and M332). M189, a known gBRCAm carrier, contained 10 
GMN positive cells which were all RAD51 negative. M250 and M332 contained 6 and 19 
GMN positive cells, respectively, which were all RAD51 positive.
 Biopsies were derived from several metastatic sites (Figure 1B). No clear differences 
in histopathologic characteristics between biopsies that resulted in successful versus 
non-successful tests were observed (Supplemental Table 1). The RECAP test could be 
performed on core needle biopsies (n=37) as well as punch biopsies (n=4) from skin 
metastases. In 19 biopsies (4 triple negative BrC (TNBC), 4 HER2 positive and 11 estrogen 
or progesterone receptor (ER/PR) positive), we determined whether standard ER, PR and 
HER2 immunohistochemistry analyses could be performed on the RECAP biopsy. This 
yielded identical results in the RECAP biopsy and in the original pathology biopsy for 18 
cases. In one case, which was originally scored as TNBC, we found 10% ER expression in 
the RECAP biopsy, which is just above the threshold for ER positivity (i.e. ≥10% in The 
Netherlands).
 Among the 41 successful RECAP test results, we identified 13 HRD, 2 HR intermediate 
(HRi) and 26 HR proficient (HRP) tumor samples (Figure 1). RECAP status was independent 
of histopathologic characteristics of the tumors, biopsy type and localization of the 
metastatic lesion (Supplemental table 2).
Molecular defects in HRD tumors 
The 13 HRD tumors were further analyzed to find a molecular explanation for the 
observed HRD phenotype (Table 1). 38% (5/13) of HRD tumors harbored germline BRCA1/2 
mutations, of which one patient harbored a BRCA2 variant of unknown significance (VUS) 
that was functionally validated for affecting HR [14]. In 15% (2/13) of HRD tumors, somatic 
BRCA2 VUSes were found, which are predicted to be non-pathogenic. BRCA1 promotor 
hypermethylation was identified in one HRD tumor and  BRCA1 RNA was indeed absent in 
this tumor as assessed by RNA in situ hybridization (Supplemental figure 2). Thus, the HRD 
phenotype was explained by a BRCA defect in 46% (6/13), leaving 54% (7/13) of the HRD 
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Change of HRD phenotype in response to DSB inducing therapy 
Next, we explored the added value of the RECAP test as a predictive biomarker to select 
patients for PARPi treatment in the metastatic setting. From three gBRCAm patients, 
who were treated with DSB inducing agents, pre- as well as post-treatment biopsies 
were subjected to the RECAP test. These tumors initially showed an HRD phenotype, 
corresponding to the BRCA deficient genotype (Figure 2). However, after patients had 
developed PD, these tumors became HRP showing reversal of the HRD phenotype.
 Patient 1 (Figure 2) harbored a BRCA2 VUS (c.9104A>C p.Tyr3035Ser) that has been 
shown to negatively affect HR efficiency and moderately increase risk of BrC [13]. A pre-
treatment biopsy from the advanced TNBC showed HRD by the RECAP test. The patient 
was treated consecutively with capecitabine, carboplatin/gemcitabine and low dose 
cisplatin in combination with nivolumab, on which she developed PD after 6 cycles. 
Subsequently, olaparib (PARPi) monotherapy was started, prior to which a second biopsy 
was obtained for RECAP testing. The second biopsy was very heterogeneous, harboring 
both HRD (RAD51 negative) and HRP (RAD51 positive) cells, overall resulting in an HRi 
phenotype. The result of the RECAP test was concordant with in vivo patient response, as 
she already showed PD after the first response evaluation at 8 weeks of olaparib treatment, 
thus primary refractory to olaparib.
 Patients 2 and 3 harbored germline mutations in BRCA1 (c.4327C>T; p.Arg1443*) 
and BRCA2 (c.5351dupA; p.Asn1784fs), respectively. The pre-treatment RECAP test 
reported an HRD phenotype in both patients. Interestingly, both tumors developed an 
HRP phenotype after they had developed resistance in response to the combination of 
carboplatin, paclitaxel and veliparib (PARPi) within a clinical trial. These three patients had 
been previously treated with anthracycline based therapy, which also induces DSB, but 
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Figure 3: BRCA1 reversion mutation explains resistance in one patient. A: An additional point mutation 
(officially: 4327_4329delinsTGG) was acquired next to the original 4327C>T mutation, resulting in restoration the 
open reading frame disrupted by the original mutation and consequently full-length BRCA1 protein production. 
B: FISH analysis showed that both pre- and post- treatment biopsies harbor 2 copies of BRCA1, indicating that the 
original mutated allele was duplicated. C: In both pre- and post-treatment biopsies loss of heterozygosity was 
observed. The tumor became HRP due to reversion of one mutant BRCA1 copy.
To unravel the molecular mechanisms leading to resistance in these patients, we searched 
for secondary BRCA1/2 mutations in the post-treatment tumor biopsies. Patient 2 acquired 
an additional point mutation, i.e. 4329A>G, (officially: 4327_4329delinsTGG) next to the 
original 4327C>T mutation, resulting in restoration of the open reading frame disrupted by 
the original mutation and consequently full-length BRCA1 protein production (Figure 3A). 
The 4327C>T mutation was observed at a MAF of 70% in the pre-treatment and 80% in the 
post-treatment biopsy, while the 4327_4329delinsTGG was present at MAF of 30% in the 
post-treatment sample. In both pre- and post-treatment biopsies loss of heterozygosity 
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was observed. Fluorescence in situ hybridization (FISH) analysis showed that both pre- 
and post- treatment biopsies harbored 2 copies of BRCA1, indicating that the original 
mutated allele was duplicated (Figure 3B). Thus, the tumor became HRP due to reversion 
of one mutant BRCA1 copy. 
 The other two patients did not show any secondary mutations in the mutated BRCA 
gene. Other mechanisms for PARPi resistance have been proposed, such as loss of 53BP1 
protein. Loss of 53BP1 was examined but not found in any resistant tumor (Supplemental 
Figure 3). In conclusion, the RECAP test detected reversal of the HRD phenotype, although 
the cause of resistance remained elusive in two out of three tumors.
CHEK2 c.1100delC mutation does not cause HRD 
In addition, one tumor clearly showed an HRP phenotype, despite harboring a germline 
BRCA2 mutation (c.3847_3848delGT; p.Val1283fs). The biopsy was taken when this patient 
showed progressive disease (PD) after 5 months of carboplatin/paclitaxel treatment, 
however HR status pre-treatment remains unknown as a fresh pre-treatment biopsy 
was not available for this patient (Figure 4). As this tumor might have developed reversal 
of the HRD phenotype, both pre- and post-treatment tumor material (70% tumor) was 
sequenced. The germline BRCA2 mutation was present at a mutant allele fraction (MAF) of 
41% and 34%, respectively, and secondary mutations were not present. The relatively low 
MAF of the germline BRCA2 mutation suggested that the BRCA2 wild-type allele was still 
present in the tumor, which was confirmed by FISH (Figure 4B). Additionally, this patient 
also carried a germline CHEK2 mutation (c.1100delC; p.Thr367fs), present at MAF 73% and 
67%, in the pre- and post-treatment biopsy, respectively. Thus, the driver mutation of this 
tumor was the CHEK2 mutation instead of the BRCA2 mutation. CHEK2 is a known BrC 
susceptibility gene, but the direct effect of CHEK2 mutations on HR status remains elusive. 
Therefore, the HR status of SUM102PT cells, which harbor the exact same c.1100delC 
mutation in CHEK2 as found in this patient, was determined and the CHEK2 c.1100delC 
mutation did not cause HRD (Figure 4D). Finally, this patient was treated with Olaparib 
therapy but was primary refractory despite her gBRCAm status. She showed PD after the 
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Discussion 
This study shows that the RECAP test is feasible (93% successful) on metastatic BrC 
biopsies, greatly enhancing its diagnostic potential and clinical applicability. The 
functional RECAP test is robust and its applicability extends from core needle biopsies 
from different metastatic sites to punch biopsies from skin metastases and test results 
are available within one week. HRD was detected in 13 out of 41 tumors (32%). Among 
13 HRD tumors only five showed a gBRCAm, indicating that the RECAP test may identify 
twice as many candidates for PARPi treatment compared with gBRCA analysis.
 We believe this study provides the first evidence that the HR phenotype, measured by 
a functional HR test, changes over time in gBRCAm patients due to previous therapies. The 
real-time HR status measured by RECAP is consistent with therapy response of patients. 
Within the current cohort, reversion of the HR phenotype was detected in three patients 
with gBRCAm tumors after developing in vivo resistance to DSB inducing therapies 
(carbo-/cisplatin or PARPi). Another gBRCAm patient, with a BRCA proficient tumor, 
showed resistance to DSB inducing agents and was refractory to olaparib, which was 
concordant with the result of the RECAP test (HRP). These cases highlight the need for HR 
tests based on the phenotype such as the RECAP test, especially in the advanced setting.
 The molecular mechanism leading to resistance and reversion of the HRD phenotype 
was explained in one of three patients by a secondary mutation in BRCA1. This is quite 
unique, as for BrC, most reversion mutations are described within BRCA2 and a BRCA1 
reversion has only been described once before [15]. The incidence of BRCA1/2 secondary 
mutations within resistant tumors is not clear yet, as most are described in case-reports or 
studies with small sample sizes. In 26 patients who had platinum-resistant recurrent ovarian 
cancer the incidence of BRCA1/2 secondary mutations was 46.2% [16]. In two out of five 
(40%) gBRCAm patients with platinum/PARPi therapy resistant metastatic BrC secondary 
BRCA2 mutations were detected in ctDNA [17]. Recent case-reports highlight that BRCA1/2 
secondary mutations are a universal resistance mechanism for different tumor types (e.g. 
prostate, pancreatic) with germline or somatic loss-of-function mutations [18-21]. However, 
since not all resistant patients harbor secondary mutations, detecting PARPi resistant 
tumors by screening for secondary BRCA mutations would lead to an underestimation 
and only identify a subgroup of resistant tumors. Yet, the RECAP test detects resistant 
tumors regardless of the exact underlying resistance mechanism. 
 Here, we show a case of coincidence of both germline BRCA2 and CHEK2 c.1100delC 
mutations in a patient with an HR proficient breast tumor. The driver mutation of this 
tumor was  CHEK2  instead of BRCA2. This highlights two important issues. First, BrC that 
arises in a gBRCAm patient is not necessarily BRCA associated and second, the CHEK2 
c.1100delC mutation does not cause HRD. Although the effect of the c.1100delC mutation 
on RAD51 focus formation has not been investigated before, it was recently reported that 
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mutations in CHEK2 were not associated with mutational signature 3 (related to DNA DSB 
repair by HR) [22].
 The major strength of this study is the functional character of the RECAP test for 
exploring the HR phenotype. Furthermore, the RECAP test is not dependent on high tumor 
percentage in a sample, since the microscopic read-out allows differentiation between 
tumor and stromal cells. Another advantage is its broad applicability: where many HRD 
tests focus specifically on TNBCs, the RECAP test detects HRD regardless of histological 
grade and subtype. Since RECAP procedures (irradiation and 2 hours culturing) do not 
influence standard hormone receptor analyses, the fresh biopsy for RECAP testing could 
also be used for diagnostic pathology analyses, thereby limiting the amount of tissue 
needed. Furthermore, its high success rate (93%) and short turnaround time make the 
RECAP test competitive in a clinical setting.
 The current study also has some limitations. First, functional testing requires fresh 
(instead of paraffin embedded) tumor specimens and for the RECAP test in particular, 
ex vivo DNA damage is induced by X-ray or gamma-irradiation. Second, the RECAP test 
cannot be completed successfully in slow growing tumors lacking proliferating cells (in 
the current study 3/44). Third, whether the RECAP test predicts PARPi or DSB inducing 
therapy response cannot be concluded from this study, although the three highlighted 
cases in this article are promising. 
 Compared with gBRCA analysis, the RECAP test may identify twice as many candidates 
for PARPi treatment. Moreover, reversion of the HR phenotype is detected by RECAP, 
identifying patients with gBRCAm who will no longer benefit from PARPi or DSB inducing 
agents due to resistance. The functional RECAP test, determining the real-time HR status 
independent of gBRCAm status, shows great potential as a predictive biomarker for PARPi 
treatment of metastatic BrCs. Clinical trials evaluating the predictive value of the RECAP 
test for in vivo response to PARPi have been initiated.  
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Supplementary Methods
BRCA1/2 sequencing and MLPA
Data on germline BRCA1/2, CHEK2 and PALB2 mutations were retrospectively obtained 
from medical records of patients who visited a clinical geneticist for genetic counseling 
and had given informed consent for sharing these data. Patients who did not visit a clinical 
geneticist gave informed consent to perform BRCA1/2 and CHEK2 sequencing of the biopsy. 
Also, pre- and post-treatment biopsies, from patients who received platinum or PARPi 
based therapies, were subjected to targeted sequencing. DNA was isolated after manual 
dissection of tumor tissue from hematoxylin stained paraffin sections and incubation 
with 5% Chelex (Bio-Rad laboratories, Hercules, CA), followed by protein kinase K (Roche, 
Mannheim, Germany) digestion overnight at 56°C. Ion semiconductor sequencing on 
the Ion Torrent Personal S5XL was performed according to manufacturer’s instructions 
(Thermo Fisher Scientific, Waltham, USA). Adapter-ligated libraries were constructed 
using the AmpliSeq Library kit 2.0 with amplicons designed targeting BRCA1/2, CHEK2 
and TP53. Generation of sequence reads, trimming adapter sequences, filtering, and 
removal of poor signal-profile reads was performed via the Ion Torrent platform-specific 
pipeline software Torrent Suite v5.2.2. Initial variant calling was performed by comparison 
to the reference genome hg19 (build 37) using the “Torrent Variant Caller v5.2.0.34” plug-
in from the Torrent Suite Software. Multiplex ligation-dependent probe amplification 
(MLPA) analysis of BRCA1 and BRCA2 was undertaken to identify large rearrangements 
using the SALSA MLPA kit P002B, and for confirmation of observed abnormalities, the 
SALSA MLPA kit P087 was used (MRC Holland, Amsterdam, The Netherlands). Analyses 
were performed according to the manufacturer’s instruction; products were run on an ABI 
automated sequencer (ABI 3730XL), and the data were analyzed by Genemarker version 
2.7.0 (Softgenetics, State College, PA). BRCA1 promoter methylation was assessed as 
previously described [13].
BRCA1/2 FISH
To determine the BRCA1/2 gene copy number, fluorescence in situ hybridization (FISH) 
was performed on 4-μm tissue sections using an in-house protocol for pretreatment 
and BRCA1 or BRCA2 and centromere control probes (Leica, Kreatech, Amsterdam, The 
Netherlands). Slides were mounted with DAPI containing Vectashield mounting medium. 
In situ detection of BRCA1 RNA 
In situ detection of BRCA1 mRNA was performed using RNAScope (Advanced Cell 
Diagnostics, Newark, USA) on the automated Ventana Discovery Ultra system (Ventana 
Medical Systems, Roche, Tucson, USA). RNAscope analysis was performed according to 
manufacturer’s instructions using the reagent kit (VS Reagent Kit 320600; Advanced Cell 
Diagnostics) on proteinase K (0.1 %, 5 min at 37 °C)-treated paraffin sections (4 µm).
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ER, PR and HER2 immunohistochemistry
ER, PR and HER2 immunohistochemistry were performed using ER (ER SP1; Ventana Medical 
Systems, Roche, Tucson, USA), PR (PR 1E2; Ventana Medical Systems, Roche, Tucson, USA) 
and HER2 (HER2 4B5; Ventana Medical Systems, Roche, Tucson, USA) antibodies. ER and 
PR status were scored positive when ≥10% of the tumor cells were positive, according to 
the Dutch Breast Cancer Guideline [23]. HER2 status was scored according to international 
guidelines [24].    
RAD51 assay on cell lines
To unravel the effect of the c.1100delC mutation in CHEK2 on HR, RAD51 focus formation 
was assessed in three BrC cell lines: T47D, MM463 and SUM102PT. Cell lines were grown 
in Roswell Park Memorial Institute (RPMI) medium with 10% Fetal Calf Serum (FCS) and 
antibiotics at 37°C and 5% CO2. Cells were seeded on coverslips one day prior to irradiation 
with 5Gy. Proliferating cells were labeled with 3μg/ml 5-Ethynyl deoxyuridine (EdU) 
(Invitrogen, Thermo Fisher Scientific, Waltham, USA). After 2 hours cells were subjected 
to pre-extraction, fixation and immunofluorescence as previously described [25]. Primary 
antibody against RAD51 (homemade) was diluted 1:10,000 and secondary antibody 
(goat-anti-rabbit 594) 1:1,000. Edu incorporation was visualized using Click-it chemistry 
with Click-it Atto fluor 488 cocktail (Invitrogen) according to manufacturer’s instructions. 
Samples were visualized using Leica SP5 confocal microscope.
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Supplementary Data
2 hour incubation 
under constant rotation
Fixation and paran embedding






RAD51 immunouorescence HE staining
Microscopic analyses
Supplemental Figure 1: Workflow of RECAP test. Fresh primary breast tumor specimens were 
collected and irradiated with 5 Gy, incubated for 2 hours before formalin fixation and paraffin 












Supplemental Figure 2: BRCA1 RNA in situ hybridization by RNAscope. M312 clearly showed 
absence of BRCA1 RNA. PPIB probe = positive control.
Supplemental Figure 3: No loss of 53BP1 in resistant biopsies.
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Supplemental table 1: Comparison of histopathologic characteristics of successful tests and non-
successful tests.


































































*independent of ER/PR status
Fisher’s exact test
ER/PR+ was defined as >10% ER+ and/or >10% PR+. HER2+ defined as immunohistochemistry (IH) 
3+ or IH 2+ and HER2 amplification detected by In situ hybridization.
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Supplemental table 2: Comparison of histopathologic characteristics of RAD51 proficient, 
intermediate and deficient metastatic biopsies.



















































































Total 26 2 13
*independent of ER/PR status
Fisher’s exact test
ER/PR+ was defined as >10% ER+ and/or >10% PR+. HER2+ defined as immunohistochemistry (IH) 
3+ or IH 2+ and HER2 amplification detected by In situ hybridization.
Supplemental table 3: in-/exclusion criteria.
Inclusion criteria
• The site of the tumor should be amendable for biopsy. NB lung metastases (high risk of hematothorax) and 
bone metastases (not suitable for ex vivo test because calcifications interfere with experimental procedu-
res) are excluded.
• Age >18 years.
• WHO performance status 0 or 1.
• Bilirubin <1.5 ULN and both AST and ALT <5x ULN in case a liver biopsy is planned.
• Platelets >100 x 10e9/L st and INR <1.5, unless platelet/INR values are not necessary according to local 
protocols or after consent of the intervention radiologist for that particular site of biopsy (e.g. biopsy of the 
breast).
• Written informed consent.
Exclusion criteria
• Current therapeutically use of anti-coagulant (coumarin derivates, warfarin, heparin or low molecular 
weight heparin [LMWH]) whereby a short interruption of drug use is not allowed. LMWH if used for prop-
hylaxis is allowed. 
• Any psychological condition potentially hampering compliance with the study protocol.
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Supplemental Table 4:  All biopsies with RAD51 counts.
Trial 
no
M code Origin Histological 
subtype






1 M184 liver ductal + - - 2 positive 92
2 M194 ovary lobular - - + 2 positive 88
3 M196 liver lobular - - - unknown positive 95
4 M207 liver ductal - - - 3 negative 9
5 M212 liver ductal + - - unknown negative 6
6 M216 pectoralis 
LN
medullary - - - 3 positive 83
7 M223 liver neuro-endocrine 
tumor
excluded
8 M222 axillary LN ductal - - - 3 negative 0
9 M226 liver ductal + + - 2 positive 78
10 M230 liver ductal - - + 3 negative 12
11 M186 axillary LN ductal + + - 3 positive 68
12 M189 liver ductal/mucinous + - - 3 inconclusive  
(<30 GMNs)
0
13 M190 mamma ductal ? ? ? 3 positive 99
14 M228 liver ductal + - - 3 positive 64
15 M234 liver ductal - - - 2 negative 0
16 no  biopsy
17 M242 cervical LN ductal - - - 3 negative 4
18 M240 mamma Not otherwise 
specified (NOS)
- + - 3 negative
2
19 M238 mamma multifocal  
(ductal + neuro-
endocrine)
+ - - 3 positive
86
20 M252 liver ductal + + - 2 positive 93
21 M250 liver ductal + - - 2 inconclusive 
(<30 GMNs) 100
22 M254 axillary LN lobular + - + unknown positive 77
23 M256 Chest wall ductal + + - 3 negative 6
24 no  biopsy
25 no  biopsy
26 M268 axillary LN ductal + + - 1 positive 94
27 M273 skin unknown + - - 2 positive 61
28 M274 skin lobular - - - unknown
not repre-
sentative
29 M282 axillary LN ductal - - + 3 negative 8
30 M283 axillary LN ductal - - + unknown negative 3
31 M290 skin ductal + + - 3 positive 74
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32 M294 axillary LN ductal + - - 3 positive 99
33 no  biopsy
34 M284 liver ductal + lobular - - + 2 positive 97
35 M293 cervical LN lobular - - + 3
not repre-
sentative
36 M299 liver ductal + - - 3 positive 97
37 M298 Chest wall ductal ? ? ? 3 intermediate 34
38 M301 cervical LN mucinous ductal + + - unknown positive 85
39 M303
Subcutane-
ous lesion ductal - - - 3 positive 85
40 M304 skin
ductal (mu-
cinous) - - + 3 positive 96
41 no  biopsy
42 M323 chest wall
ductal 
(sarcomatoid) - - - 3 positive 87
43 M316 axillary LN ductal ? ? ? 3 positive 95
44 M313 liver unknown + - - unknown intermediate 26
45 M314 presternal ductal + + - 2 positive 94
46 M312 cervical LN ductal - - - 3 negative 1
47 M315 skin ductal - - + 3 positive 90
48 no  biopsy
49 M317 liver ductal + - - 3 negative 2
50 M319 liver unknown - - - 2 positive 87
51 M321 mamma ductal - - - 3 negative 10
52 M324 mamma ductal + + - 3 positive 84
53 M330 parasternal unknown - - - 3
not repre-
sentative
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Summary 
This thesis describes the improvement of biomarker development and therapy response 
prediction for breast cancer (BC) patients using functional tissue-based assays. Both 
targeted treatment strategies and classic chemotherapy require predictive biomarkers to 
guide clinical decision making. Targeted therapy with PARP inhibitors is available for breast 
and ovarian cancer patients with germline BRCA1/2 mutation status, which is currently the 
only predictive biomarker for PARP inhibitor treatment. However, through patient selection 
based on the homologous recombination (HR) status of the tumor, instead of germline 
BRCA mutation status, the population of BC patients that could benefit from PARP inhibitor 
treatment can be enlarged. Chemotherapy remains the cornerstone of BC treatment 
and currently no standard biomarkers exist for response prediction, despite decades of 
biomarker driven research. Traditional biomarker assessment is executed on fixed tissue 
specimens or through genetic testing, but the difficulty to translate this information to 
tumor behavior necessitates development of tools to select patients for therapies based 
on tumor phenotype rather than genotype. Prediction of individual treatment responses 
by functional ex vivo assays may fill this knowledge gap. Functional assays are generally 
performed in primary cell cultures or animal models (patient derived xenografts). In this 
thesis, a novel approach to biomarker discovery is described: the measurement of the 
actual response of an individual BC tissue specimen to ex vivo chemotherapy or radiation.
 First, an overview of ex vivo tumor culture systems for functional drug testing and 
therapy response prediction is provided in chapter 2. In this review we discuss the 
advantages and disadvantages of several ex vivo tumor culture systems such as primary 
cultures, spheroids, organoids and tissue slices. A key message in this chapter is that 
organotypic tissue slices are the best model of maintaining intratumoral heterogeneity 
and tumor-stromal interactions. Organotypic tissue slices are widely applicable in both 
translational research and personalized medicine, as almost any relevant treatment could 
be tested in this system. In the future, these tissue based ex vivo sensitivity assays could 
individualize therapy response prediction for patients in clinical practice.
 In chapter 3, we provide evidence that the REpair CAPacity (RECAP) test, a functional 
assay exploiting the formation of RAD51 foci in proliferating cells after ex vivo irradiation 
of fresh BC tissue, identifies homologous recombination deficient (HRD) tumors and we 
demonstrate its reproducibility in an extensive cohort of primary BCs. The RECAP test 
is successfully completed in the great majority of the cases (74%) in what is by far the 
largest set (n=125) of functional HR capacity assays performed on fresh BC specimens. 
Approximately two-third of the HRD cases can be explained by BRCA gene defects, while 
several of the non-BRCA HRD tumors also showed mutational ‘BRCAness’ signatures, 
suggesting that these are also bona fide HRD cases. The large cohort size allowed us 
to link HRD to increased incidence of high tumor infiltrating lymphocyte (TIL) counts 
and microsatellite instability (MSI). The main clinical implications of this study are that 
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the RECAP test identified 50% more patients eligible for PARP inhibitor treatment than 
germline BRCA analysis alone and that this group of tumors may also contain tumors that 
may benefit from immunotherapy. 
 Functional HR assessment by the RECAP test produces a unique real-time measure 
of the HR status, as can be read in chapter 4. HRD was detected in 13 out of 41 biopsies 
(32%) analyzed metastatic BC lesions. Among 13 HRD tumors only five showed a germline 
BRCA mutation, indicating that the RECAP test identifies approximately 60% more patients 
who may benefit from PARP inhibitor treatment than germline BRCA analysis only. From 
three patients with germline BRCA mutated tumors, paired-biopsies were available before 
and at disease progression after treatment with double strand break (DSB) inducing 
chemotherapy. Reversion of the HR phenotype (from HR deficient to HR proficient/
intermediate) was discovered, highlighting the clinical need for phenotype based HRD 
tests such as the RECAP test to guide treatment choice. BRCA reversal in one of three DSB 
inducing therapy resistant patients was caused by a secondary mutation in BRCA1. For the 
other two patients, the mechanism of resistance remains to be elucidated. The RECAP test 
is thus capable of detecting resistance among reverted germline BRCA mutated tumors, 
regardless of the knowledge of the exact underlying resistance mechanism. Therefore, the 
RECAP test shows great potential for prediction of sensitivity to DSB inducing therapy in 
metastatic BC patients, who have been treated with multiple lines of previous therapies 
that could have caused BRCA/HRD status reversal.
 In chapter 5, a large cohort (n=71) of breast tumors with known functional HR status, 
measured by RAD51 focus formation after irradiation, was subjected to other genomic scar 
based HRD tests (BRCA1/2-like classifier and CHORD). For a subset (n=54) whole genome 
sequencing was performed to further characterize HRD tumors and especially the non-
BRCA related HRD tumors. We demonstrate that only half of the non-BRCA related RECAP-
HRD tumors were also classified as HRD by other HRD tests. In vivo therapy response of 
some HRD tumors were available. The main implication of this chapter is that different 
HRD tests (including the RAD51 based functional assay and HRD-genomic scars) do not 
identify exactly the same population of BC patients (60-70% concordance between tests). 
In the future, multiple HRD tests should be included in a clinical trial to determine how 
well these tests predict in vivo response, as it is not yet possible to choose one ultimate 
HRD test.
 Chapter 6 describes the development of a sensitivity assay for cisplatin chemotherapy 
by performing ex vivo treatment on organotypic tissue slices from histological biopsies of 
metastatic BC lesions. The novel scientific value of this is two-fold and has both technical 
and clinical implications. First, this chapter describes that ex vivo drug screening on 
organotypic tissue slices is feasible using limited histological biopsy material as input 
instead of larger pieces of tissue from resections. Second, the ex vivo drug sensitivity of 
organotypic tumor slices was compared with the in vivo responses of patients. The ex vivo 
sensitivity assay described in this chapter measures the actual response of the tumor 
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of an individual patient to a certain therapy, which might be a more accurate method 
for predicting chemotherapy response than using predictive biomarkers that generally 
correspond to a better outcome.
 The results of a functional homologous recombination screen in 54 breast and 38 
ovarian cell lines are shown in chapter 7. HRD was found among 19% (10/54) of the 
BC and in 8% (3/38) of the OC cell lines. Of these HRD cell lines 77% (10/13) were not 
explained by a BRCA defect. One non-BRCA related cell line harbored an EXO1 mutation 
that could explain its HRi phenotype. Among the BRCA mutated cell lines, HRD was absent 
in 56% of the BC (5/9) and 38% of the OC (3/8) cell lines. In four of these cases, a putative 
cause for the discrepancy was found, such as loss of SHLD2. Further research is ongoing 
to unravel the discrepancies between BRCA mutation and functional HR status. HRD cell 
lines comprise a heterogeneous group in which not all cell lines represent BRCA deficient 
or HRD tumor specimens. Since cell lines are so broadly applied as model systems for a 
wide range of experiments across all fields of cancer research, it is of utmost importance 
to realize that the specific cell line used influences the conclusions that are drawn from 
these experiments tremendously.
 In conclusion, the studies described in this thesis use functional assays on tumor tissue 
to improve the selection of BC patients for double strand break inducing chemotherapy 
and PARP inhibitor therapy. This represents a novel approach to biomarker discovery: 
the measurement of the actual response of an individual BC tissue specimen to ex 
vivo chemotherapy or radiation. In the future, these tissue based ex vivo assays could 
individualize therapy response prediction for patients in clinical practice.
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General discussion and future perspectives
Since breast cancer (BC) is the most common malignancy in women with the second 
highest cancer related mortality rate, more research is needed to improve patient 
outcomes. New knowledge is generated in the laboratory through fundamental research, 
but what do these findings mean for patients? The gap between a laboratory bench and 
a hospital bed is not only physically but also figuratively large. Translational research 
is required to channel the data that is being generated at that laboratory bench into 
the direction of the hospital beds. By collaborations among fundamental researchers, 
translational researchers and medical doctors, research findings can be translated in 
knowledge that has clinical utility and applicability.
 The development of new anticancer therapies only contributes to improvement 
of patient outcomes when the right therapy is administered to the right patient. Over 
the last decades, cancer treatment has moved from ‘one-size-fits-all’ regimens towards 
more personalized cancer therapy. Therefore, the need for better predictive biomarkers 
is imperative. Biomarker-driven research has yielded strong predictive biomarkers that 
correlate with patient response to a certain drug. For example, the monoclonal antibody 
trastuzumab, targeting HER2, dramatically improved survival for patients with BC 
overexpressing HER2. However, for many other therapies, predictive biomarkers do not 
yet exist. 
 Besides specific molecular markers (such as BRCA mutation status in BC) the field of 
biomarker discovery has moved to genomic, transcriptional and proteomic predictive 
signatures. As next-generation sequencing techniques are becoming more and more 
common and affordable, whole genome sequencing is exploited to characterize 
individual patients and predict therapy response. However, validation of these biomarkers 
and subsequent integration in the diagnostic process are major bottle-necks that require 
extensive research. For example, there are concerns regarding turn-around time of the 
generation of these biomarkers, what to do with variants of unknown significance, 
whether the tests detect historic events or reflects real-time tumor characteristics and 
how to cope with complex data analyses. It is a long road from biomarker discovery and 
assay development to implementation in the clinic.
 As therapy response often cannot be predicted accurately by a single genetic marker 
only, alternative ways of patient stratification are needed. Beyond mutational status, many 
other factors influence tumor behavior and therapy response, for example epigenetic 
factors and the tumor microenvironment. Therefore, the current difficulty to translate 
genetic information to tumor behavior necessitates development of tools to select 
patients for therapies based on tumor phenotype rather than genotype. Ex vivo assays 
that predict therapy response may fill this knowledge gap.
 The general aim of this thesis was to improve biomarker development and therapy 
response prediction for BC patients using functional tissue-based assays. This thesis 
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demonstrates that selection of patients for precision therapies should ideally be based on 
the tumor phenotype, since the tumor (HR) phenotype changes over time due to previous 
therapies. This is exemplified in chapter 4, where reversion of the HR phenotype was 
detected in three patients with germline BRCA mutated tumors after developing in vivo 
resistance to DSB inducing therapies. The real-time HR status measured by the RECAP test 
was consistent with therapy response of patients. These cases highlight the need for HR 
tests based on the phenotype such as the RECAP test, especially in the advanced setting. 
Chapter 3 reflects the power of functional phenotype based testing: more patients who 
are eligible for PARP inhibitor or DSB inducing chemotherapy treatment are identified 
than by analysis of a single genetic marker only (germline BRCA analysis). Chapter 7 
demonstrates that this is also true in a well characterized selection of cell lines. Chapter 
5 shows that functional phenotype based testing and genomic based assays result in 
a partially different HR classification of tumors. To elucidate the consequences of this 
different classification, clinical trials should include multiple HRD tests to determine how 
well these tests are able to predict in vivo response to PARP inhibitor therapy. Next, therapy 
response prediction based on the tumor phenotype has broad applicability beyond the 
scope of this thesis. Organotypic tissue slices are widely applicable in both translational 
research and personalized medicine, as they can be used to test many relevant treatments 
on many different solid tumor types. Chapter 6 describes the first steps towards functional 
ex vivo testing of organotypic tissue slices from small core needle biopsies, making the 
technique more useful as a drug screening tool in the clinic. Functional ex vivo assays may 
be the ultimate selection method when unique genetic markers have not been identified 
for particular drugs or do not suffice (e.g. in metastatic setting or after multiple lines of 
therapy).
Future perspectives
The studies presented in this thesis have generated new insights in functional tissue 
based therapy prediction. The first step towards clinical implementation of functional 
diagnostics is to determine and validate whether the assays predict in vivo response to 
relevant therapies. Therefore, we have recently initiated two clinical proof-of-concept trials 
specifically powered to determine the predictive value of i. the RECAP test [FUnctional 
selection of advanced breast cancer patients for Talazoparib treatment Using the REpair 
capacity test (FUTURE) study, Trialregister.nl/trial/8099], and ii. sensitivity assays that 
use organotypic slices from histological biopsies [BReast cancer Ex vivo Anthracycline 
Sensitivity Test (BREAST) study, trialregister.nl/trial/5588]. Both the RECAP test and ex vivo 
chemotherapy sensitivity testing (for example for anthracyclines) could be applied in the 
neoadjuvant as well as the advanced setting.
 The aim of the FUTURE study is to assess the predictive potential of the RECAP test for 
in vivo response to PARP inhibitor therapy (Talazoparib) among high grade ER positive/
HER2 negative or triple negative BC patients by investigating the percentage of patients 
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with HRD breast tumors, as determined by the RECAP test, with PFS on Talazoparib 
monotherapy of 4 months or longer. 
 The aim of the BREAST study is to determine the concordance between the ex vivo 
anthracycline sensitivity test and in vivo response to anthracycline-based neoadjuvant 
chemotherapy. Also, optimal cut-off values for the ex vivo anthracycline sensitivity assay 
are determined to carefully predict in vivo anthracycline response. Patients with primary 
BC, who are scheduled to be treated with anthracycline-based neoadjuvant chemotherapy 
are scheduled for a study-specific pre-treatment tumor biopsy for the ex vivo sensitivity 
test. The primary end point is the concordance between the ex vivo anthracycline 
sensitivity test and the in vivo response to anthracycline-based NAC on MRI. 
Besides the translation and implementation of tissue based ex vivo assays to and in the 
clinic, it is important to extend the use of these assays. Functional diagnostics is a broadly 
applicable method, that can be used for many different types of drug sensitivity screening 
and has applicability beyond BC to many different solid tumor types. Ex vivo tissue 
slices have been generated and successfully cultured for many different tumor types, 
however drug sensitivity screening is performed seldom on tissue slices. In our lab, the 
chemotherapy sensitivity assay using BC tissue slices has been employed for predicting 
response to anthracyclines and cisplatin therapy. Currently, we are adapting the assay to 
more specifically predict response to taxane-based chemotherapies. 
 Since only a limited number of tissue slices can be obtained from one core needle biopsy, 
future research should be focussed on how to generate as much knowledge as possible 
from limited material. Until now, analyses of tissue slices included traditional morphologic 
assessment by haematoxylin and eosin staining as well as immunofluorescence, 
requiring a tissue slice to be fixed after a certain amount of cultivation time. In the future, 
technical improvements in the microfluidics and cancer-on-chip field might facilitate 
high-throughput cultivation and analysis of tissue slices. Nevertheless, cancer tissue is 
heterogeneous and a tumor biopsy is not comprised solely of tumor cells, neither are these 
tumor cells distributed equally in the entire biopsy. Therefore, dividing the biopsy into 
many smaller pieces for separate analyses reduces the chance of obtaining interpretable 
results. Moreover, advances in live-imaging microscopy and the use of fluorescent probes, 
could facilitate a single tissue slice to be analysed at multiple time points. Fluorescent 
probes are already available to assess several cellular processes, such as apoptosis and 
fibrosis. New developments in the laboratory are continuing to complement the toolkit 
necessary for fresh tissue analyses. However, to develop functional diagnostics further, 
more clinical trials should include a biopsy to generate tissue slices and allow correlation 
between tissue-based sensitivity screening and therapy responses of patients. This 
clinical validation is required before fresh tissue-based functional diagnostics can be 
implemented in the routine clinical diagnostic process. 
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Dit proefschrift beschrijft hoe bij borstkanker patiënten door middel van functionele 
weefsel-gebaseerde testen het effect van behandeling met specifieke geneesmiddelen 
beter voorspeld kan worden. Voor de keuze van de behandeling, of dit nu geavanceerde 
toegespitste therapieën (‘targeted therapies’) of klassieke chemotherapie is, is het noodzakelijk 
om specifieke tumor of patiënt kenmerken (‘biomarkers’) te identificeren die voorspellen 
of een patiënt zal reageren op de betreffende therapie. Behandeling met een specifieke 
doelgerichte behandeling (te weten PARP remmers) wordt momenteel toegepast bij borst- of 
eierstokkanker patiënten met een kiembaan mutatie in het BRCA1 of BRCA2 gen. Echter, door 
patiënten te selecteren op basis van de homologe recombinatie (HR) status van de tumor, in 
plaats van BRCA1/2 kiembaan mutatie status, kunnen meer patiënten geïdentificeerd worden 
die mogelijk baat hebben bij deze behandeling. Behandeling met klassieke chemotherapie 
blijft de hoeksteen van borstkanker behandeling, terwijl ondanks jarenlang onderzoek nog 
steeds geen standaard biomarker beschikbaar is voor deze therapie. Traditionele biomarkers 
worden bepaald in gefixeerde weefsels of door middel van genetische testen, maar omdat 
deze informatie niet altijd het gedrag van de tumor reflecteert, is het belangrijk om nieuwe 
methoden te ontwikkelen om patiënten voor behandelingen te selecteren op basis van het 
fenotype van hun tumor in plaats van het genotype.  Het voorspellen van de individuele 
therapie respons van een patiënt is mogelijk met behulp van functionele ex vivo testen. 
Functionele testen worden over het algemeen vooral uitgevoerd op primaire cel culturen 
of in diermodellen (zogenoemde patient derived xenografts). In dit proefschrift wordt een 
nieuwe aanpak voor biomarker ontwikkeling getoond: het meten van de respons van een 
individueel borstkanker weefselplakje op ex vivo chemotherapie behandeling of bestraling.
 Allereerst, wordt er in hoofdstuk 2 een overzicht gegeven van verschillende ex vivo 
tumor kweeksystemen om functioneel therapierespons te testen. In dit review beschrijven 
we de voor- en nadelen van de verschillende systemen die over het algemeen gebruikt 
worden om tumoren ex vivo te kweken, zoals: primaire cel culturen, spheroïden, organoïden 
en weefselplakjes. De hoofdboodschap van dit hoofdstuk is dat weefselplakjes het beste de 
intratumor heterogeniteit en tumor-stromale interacties behouden. Weefselplakjes kunnen 
toegepast worden in zowel translationeel onderzoek als in patiëntenzorg bij het voorspellen 
van individuele therapie responsen van patiënten, aangezien bijna elk relevant middel op 
deze manier getest kan worden. In de toekomst kunnen dit soort weefsel gebaseerde ex vivo 
sensitiviteitstesten bijdragen aan het individualiseren van therapierespons voorspelling voor 
patiënten in de dagelijkse klinische praktijk.
 In hoofdstuk 3 beschrijven we de REpair CAPacity (RECAP) test, een functionele test 
die homologe recombinatie deficiënte (HRD) tumoren identificeert. Daarbij wordt gebruik 
gemaakt van ophoping van het RAD51 eiwit in prolifererende cellen na ex vivo bestraling 
van vers borstkanker weefsel. We laten in een groot cohort van primaire borstkankers 
zien dat deze test reproduceerbaar is. We beschrijven de grootste set (n=125) van verse 
A
197
borstkanker weefsels waarop een functionele bepaling van de HR status werd uitgevoerd, 
die in de overgrote meerderheid van de gevallen (74%) succesvol bleek. Ongeveer twee-
derde van de HRD tumoren hadden een mutatie in een van de BRCA genen. De overige niet 
BRCA gemuteerde HRD tumoren lieten soms ook ‘BRCAness’ mutatie profielen zien. Door de 
grootte van dit cohort, konden we HRD associëren met hoge aantallen tumor infiltrerende 
lymfocyten (TILs) en microsatelliet instabiliteit (MSI). De voornaamste klinische implicatie van 
deze studie is het feit dat de RECAP test 50% meer patiënten kan identificeren die mogelijk 
baat hebben bij PARP remmers dan kiembaan BRCA1/2 mutatie analyse en dat een deel van 
deze patiënten mogelijk ook baat hebben bij immunotherapie.
 De functionele HR bepaling door middel van de RECAP test produceert een unieke ‘real-
time’ maat van de HR status, zoals beschreven wordt in hoofdstuk 4. HRD werd gevonden 
in 13 van de 41 geanalyseerde biopten (32%). Van deze 13 HRD biopten bevatten slechts 
vijf een kiembaan mutatie in BRCA1/2, wat aangeeft dat de RECAP test ongeveer 60% meer 
patiënten kan identificeren die baat kunnen hebben bij PARP remmers. In deze studie waren 
er drie patiënten met een kiembaan BRCA1/2 mutatie, bij wie zowel voor als na therapie 
met dubbel strengs breuk inducerende chemotherapie een biopt was afgenomen. Door het 
bestuderen van dit weefsel ontdekten wij dat er een reversie van de HR status was opgetreden 
(van HR deficiënt naar HR proficiënt/intermediair), wat de behoefte voor functionele testen, 
gebaseerd op het tumor fenotype, zoals de RECAP test voor het voorspellen van tumor 
respons extra benadrukt. Bij één van deze drie patiënten werd een specifieke oorzaak van 
de reversie gevonden: er was sprake van een secundaire mutatie in BRCA1 waardoor er 
weer functioneel BRCA1 eiwit geproduceerd kon worden. Voor de andere twee patiënten 
is het resistentie mechanisme onbekend. De RECAP test herkent dus resistentie binnen 
BRCA gemuteerde tumoren, zonder dat de daadwerkelijke onderliggende oorzaak bekend 
hoeft te zijn. De RECAP test heeft daarom potentie om gevoeligheid voor dubbelstrengs 
breuk inducerende chemotherapie en PARP remmers te voorspellen in patiënten met 
gemetastaseerd borstkanker, die al met meerdere lijnen chemotherapie behandeld zijn, wat 
mogelijk HR reversie tot gevolg heeft gehad.
 In hoofdstuk 5, werden in een groot cohort (n=71) van borstkanker patiënten de reeds 
bekende functionele HR status, bepaald door de RECAP test, vergeleken met de resultaten 
van HRD testen gebaseerd op “genomische littekens” als teken van HR deficiëntie (BRCA1/2-
like classifier en CHORD). Voor een deel van de tumoren (n=54) werd de sequentie van het 
gehele genoom bepaald om het HRD fenotype, en met name de niet BRCA gemuteerde HRD 
tumoren, verder te onderzoeken. Het bleek dat slechts de helft van de niet BRCA gemuteerde 
RECAP-HRD tumoren ook HRD werd bevonden door een andere HRD test. In vivo therapie 
respons was bekend voor enkele tumoren. De belangrijkste conclusie van dit hoofdstuk is 
dat verschillende HRD testen niet precies dezelfde populatie patiënten identificeren (60-
70% concordantie tussen de testen). In de toekomst zullen meerdere HRD testen toegepast 




kunnen voorspellen, aangezien er op basis van de huidige gegevens nog niet één ultieme 
HRD test gekozen kan worden.
 Hoofdstuk 6 beschrijft de ontwikkeling van een gevoeligheidstest voor een ander 
antikanker middel, te weten cisplatine, door ex vivo behandelingen uit te voeren op 
weefselplakjes van biopten van gemetastaseerde borstkanker laesies. Dit heeft zowel 
technische als klinische implicaties. Ten eerste, dit hoofdstuk beschrijft dat ex vivo 
gevoeligheidstesten ook op weefselplakjes van kleine histologische biopten technisch 
haalbaar is en niet alleen op grotere stukken resectiemateriaal zoals in eerdere studies. Ten 
tweede, de ex vivo gevoeligheden werden vergeleken met in vivo respons van patiënten. 
De cisplatine ex vivo gevoeligheidstest meet de respons van de tumor van een individuele 
patiënt op een bepaalde behandeling, in plaats van het voorspellen van de respons op basis 
van predictieve factoren die over het algemeen correleren met een betere uitkomst.
 De resultaten van een functionele homologe recombinatie (HR) screen in 54 borst- en 
38 ovariumkanker cellijnen worden gepresenteerd in hoofdstuk 7. HRD werd gevonden 
in 19% (10/54) van de borst- en in 8% (3/38) van de ovariumkanker cellijnen. In deze 
cellijnen werd HRD in 77% (10/13) niet veroorzaakt door een BRCA defect. Eén niet BRCA 
gerelateerde cellijn bevatte een EXO1 mutatie die mogelijk het intermediaire HR fenotype 
verklaart. Omgekeerd bleek van de BRCA gemuteerde cellijnen 56% van de borst- (5/9) en 
38% van de ovariumkanker cellijnen OC (3/8) niet HRD. In vier van deze cellijnen werd een 
mogelijke oorzaak voor de discrepantie gevonden, zoals verlies van SHLD2. Verder onderzoek 
is onderweg om de discrepanties tussen BRCA mutatie status en functionele HR status te 
verklaren. BRCA deficiënte en/of HRD cellijnen kunnen onderling erg verschillen en niet elke 
BRCA gemuteerde cellijn vertegenwoordigt BRCA deficiënte of HRD tumoren. Aangezien deze 
cellijnen voor veel verschillende soorten experimenten gebruikt worden als modelsystemen 
in alle mogelijke onderzoeksvelden, is het erg belangrijk dat men zich realiseert dat de 
specifieke cellijn die gebruikt wordt de conclusies van het experiment enorm beïnvloedt. 
 In conclusie, de studies in dit proefschrift maken gebruik van functionele testen op tumor 
weefsel om zo bij borstkanker patiënten beter de respons op chemotherapie of PARP remmers 
te verbeteren. Dit is een nieuwe vorm van biomarker ontwikkeling: de daadwerkelijk respons 
van een individueel borstkanker weefselplakje op ex vivo behandeling met geneesmiddelen 
of bestraling wordt gemeten. In de toekomst kunnen deze weefsel gebaseerde ex vivo 
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In de wetenschap, streven we altijd naar zo veel mogelijk ‘exposure’. We presenteren 
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mogen werken. Ik wil je bedanken voor je toewijding en voor onze gezamenlijke 
reflectiemomentjes en gezellige babbels. Ik wens je heel veel succes en vooral plezier bij 
het afronden van je PhD. Ik ben ontzettend benieuwd wat er in de FUTURE voor ons in het 




Lieve familie en vrienden, de laatste paragrafen zijn voor jullie. Het afgelopen jaar is een 
bijzondere geweest, met weinig tijd voor andere zaken dan zorgen dat dit proefschrift op 
tijd af kwam en zorgen dat Krijn groter werd. Dit proefschrift is nu af en Krijn al aanzienlijk 
groter, dus langzaamaan komt er weer meer tijd vrij voor gezelligheid! Sahar, Rob, Floor 
& Martijn, Burc, Debbie en Fatma, oftewel Co-groep Lingo: wat hebben we altijd een lol 
samen. Dankjulliewel voor alle gezellige momenten met spinazieflapjes, barbecuemasters, 
borek en pannenkoeken!! Natasja en Boukje, dankjulliewel voor onze mooie vriendschap 
die in de collegebanken is ontstaan. Ik waardeer dat jullie altijd interesse hebben getoond 
in mijn onderzoek en ik hecht veel waarde aan onze gezellige momenten samen. 
Celeanummeiden, Marijke, Lisanne, Marloes, Eline, Anna, Eleonore en Hanne, wat kennen 
wij elkaar al lang! Als we elkaar zien is het altijd als vanouds gezellig! Dankjulliewel voor 
jullie vriendschap!
Lieve Mirjam, papa en mama, dankjulliewel voor jullie oneindige steun en toeverlaat. Jullie 
staan altijd voor ons klaar en ook op momenten dat ik door de bomen het bos niet meer zie, 
weten jullie alles altijd weer te relativeren. Jullie hebben mij het belang van een positieve 
instelling en hard werken meegegeven. Richard, Anita en Wendy, ik wil jullie bedanken 
voor jullie steun. Ik voel me altijd thuis bij jullie en waardeer jullie hulp ontzettend. It takes 
a village to raise a child, toch? Corrie en Juno, dank voor jullie belangstelling tijdens mijn 
promotietraject en steun bij mijn ontdekkingsreis in het moederschap. Oma Lum en opa 
Leo, wat ben ik trots dat ik nog een oma heb en dat Krijn zelfs nog een overgrootoma én 
overgrootopa heeft! Lieve Tim en Krijn, mijn mannen. Tim, je bent mijn rots in de branding 
en ik wil niets liever dan samen gelukkig oud worden. Nu is dat het afgelopen jaar al goed 
gelukt, dat ouder worden dan;) Krijn, je bent mijn kleine lachebek. Wat herken ik al veel 
van mijzelf in jou! Jullie zijn mijn alles.
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